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Preface 
PREFACE 
Short bowel syndrome is a state of malabsorption and malnutrition after a major 
resection of the small intestine that may also include some or all of the large 
intestine. The underlying disorders requiring such a major resection in children 
include small bowel atresias, malrotation with midgut volvulus, gastroschisis, 
necrotizing enterocolitis, and extensive aganglionosis. In adults, vascular 
accidents, traumatic disorders, or diffuse intestinal diseases such as Crohn's 
disease and radiation enteritis may demand massive intestinal resection. 
Total parenteral nutrition is a lifesaving therapy for these patients, indispensable 
in the early phase of short bowel syndrome. Gradually, varying from a few 
months to over one year, the remaining intestine adapts to the loss of the bowel 
and oral intake is progressed until intravenous alimentation can be stopped. 
Unfortunately, part of these patients never reach this final stage and remain 
totally dependent on total parenteral nutrition. This chronic, intravenous feeding 
has many disadvantages. Patients are limited in their lifestyle due to this time-
consuming therapy, but moreover at the long-term a number of serious 
complications such as catheter sepsis and liver impairment may occur. In 
children these problems are accentuated because of more specific nutritional 
requirements associated with growth. 
Small bowel transplantation would be the treatment of choice for these patients. 
However, many problems still hamper successful clinical small bowel 
transplantation. The vigorous and uncontrollable rejection reaction elicited 
against a small bowel allograft is probably the key event leading to a series of 
other complications, notably malfunctioning of the graft, sepsis, and peritonitis. 
This thesis outlines the problems that surround small bowel transplantation, and 
presents experiments performed in rats on rejection and graft-versus-host disease, 
their suppression, and the nutritional function of small bowel grafts, with the 
ultimate goal to obtain a long-term surviving, properly functioning small bowel 
transplant. 
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CHAPTER 1 
GENERAL INTRODUCTION 
submitted for publication to Transplant. Int. 
R.W.F. de Bruin, E. Heineman and R.L. Marque!. 
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Small bowel transplantation (SBT) would be the treatment of choice for patients 
suffering from the short bowel syndrome. Although in some centers SBT in 
patients is done with a considerable degree of success (Grant et al 1990, Todo 
et al. 1992), it is by no means an established and widely applicable therapy for 
those with short bowel syndrome. The small bowel is unique among vascularized 
organ grafts because it not only elicits a vigorous rejection reaction, but is also 
capable of inducing graft-versus-host disease (GVHD). Rejection of the graft 
does not only lead to loss of function, but also to bacterial translocation. The 
risk of fatal sepsis is aggravated by the immunosuppression given to prevent 
rejection. This chapter describes the history of experimental and clinical SBT, 
and outlines recent developments and future prospects concerning this theoreti-
cally optimal treatment modality for patients who would be dependent on total 
parenteral nutrition (TPN) for life. 
HISTORY 
In 1959, Lillehei et al. described for the first time a technique for orthotopic 
SBT in the dog. Many experimental studies followed, and several patients 
received a small bowel transplant. Enthusiasm for SBT waned because rejection 
and sepsis appeared to be insolvable problems, and because TPN was introduced 
as satisfactory therapy for otherwise untreatable patients. With the introduction 
of cyclosporine A (CsA) as powerful immunosuppressive agent, a renewed 
interest in SBT emerged, and it is now on the verge of becoming an established 
procedure in transplant medicine. 
EXPERIMENTAL MODELS OF SMALL BOWEL TRANSPLANTATION 
A number of models are used to study SBT, each having its own advantages and 
drawbacks. Monchik & Russell (1971) first used parent and F1-hybrid rats in 
SBT. By using rats of 2 inbred parent strains (P) and their offspring (F1) they 
were able to dissect graft-versus-host disease and rejection. Transplantation from 
P to F1 produces only GVHD, whereas in the reverse combination only rejection 
occurs. The relevance of these one-way semi-allogeneic models for the clinical 
12 
General introduction 
situation, in which both GVHD and rejection may occur is uncertain (Saat et a!. 
I989), and hence fully-allogeneic combinations in which the graft is transplanted 
from PI to P2 are used to study the possible interaction between GVHD and 
rejection. Syngeneic transplantation from PI to PI can be used to study the 
effects of ischaemia and lymphatic and neural disruption, while the 
immunologically induced traumas are circumvented (Table I). In large animals, 
syngeneic transplantation finds its equal in autotransplantation, in which the 
arterial and venous blood supply are divided and reanastomosed, the lymphatics 
and nerves are disrupted, and the bowel is cut and reanastomosed (Lillehei et a!. 
1959, Raju eta!. 1989, Meijssen et al. I99I'). 
Table 1. lmmunologic reactions after SBT. 
Model 
P1- Pl 
Fl-P 
P- FI 
Pl- P2 
GVHD 
+ 
+ 
rejection 
+ 
+ 
With respect to the position of the bowel 2 models are used. The bowel can be 
placed heterotopically; the recipient small bowel remains in situ, and the graft is 
placed as a Thiry-Vella fistula with both ends of the graft anastomosed as stomas 
in the abdominal wall of the recipient. The oral end of the graft may also be 
ligated or placed as a jejunostoma, whereas the distal end is anastomosed end-
to-side to the terminal ileum of the recipient bowel. 
In the orthotopic model, the recipient small bowel is resected and the graft is 
placed in continuity with the remaining duodenum and terminal ileum of the 
recipient. In this model recipient survival is dependent on functioning of the 
graft. Although orthotopic SBT (OSBT) may be the preferred model (Lee & 
13 
Chapter I 
Schraut 1986', Grant et a!. 199la), the reported longer operative time and higher 
incidence of complications (Kort et a!. 1973, Koltun et a!. 1987) have resulted in 
a number of studies in which heterotopic SBT (HSBT) have been used (Watson 
et a!. 1988). In skilled hands, however, operative time and technical success-rate 
for both techniques is not significantly different (Zhong et a!. 1990). Results 
obtained after HSBT and OSBT are not comparable (Lee & Schraut 1986', 
Grant et a!. 1991'). After HSBT, rejection of the graft is defined as the develop-
ment of a palpable abdominal mass and necrosis of stomas (Lee & Schraut 
1986', Grant et al. 1990). However, the graft may become encapsulated and 
fibrotic rather than necrotic and perforated, and the recipient may survive 
despite the graft loss, which makes the end point of rejection more difficult to 
define (Schraut et al. 1985, Grant et al. 1991'). Moreover, probably due to lack 
of intraluminal nutrients, atrophy of the mucosa occurs (Williamson & Chir 
1978), and the permeability of these grafts 7 days postoperatively is significantly 
higher than after OSBT. Graft survival after HSBT can be prolonged more easily 
than after OSBT (Grant et a!. 1991'). In conclusion, OSBT may be the preferred 
model for both immunologic and functional studies. 
Venous drainage of the graft may be in the portal or in the systemic circulation. 
Although technically more demanding (Shaffer et al. 1988), portoportal drainage 
is the more physiologic route. Beneficial effects of this route on graft survival 
have been reported (Kart et al. 1973, Schraut et al. 1985), although they may be 
of minor importance (Lee & Schraut 1986'). Porto-caval shunting may cause 
metabolic complications, such as a rise in blood ammonia levels, and liver 
atrophy. The effects of portocaval shunting after SBT appear to be minor, and 
either type of venous drainage may be used safely (Koltun et a!. 1987, Schraut et 
a!. 1986, Shaffer et al. 1989, Kaneko et al. 1991). 
Lillehei et a!. (1959) were the first to describe a technique for functional bowel 
transplantation in the dog. After removal of the bowel it was auto-transplanted 
with good function thereafter. Different models of heterotopic and orthotopic 
placement of the bowel, with either systemic or portal venous drainage, are used 
as preclinical models for both immunologic and functional studies. For practical 
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reasons the pig is also used in SBT (Grant et al. 1988, Kaneko et al. 1991). 
IDSTOLOGY 
The sequence of histologic changes after SBT is well-defined, although slight 
differences occur, depending on the model studied (Holmes et al. 1971, Monchik 
& Russel 1971, Madara & Kirloman 1985, Schmid et al. 1989). 
In our BN to WAG fully-allogeneic orthotopic total SBT model, early intestinal 
lesions on days 4-6 posttransplant were characterized by mild infiltration of the 
lamina propria and submucosa by mononuclear cells and neutrophils and by mild 
multifocal death of crypt epithelial cells. The number of mononuclear cells 
increased to moderate over a few day period, while only few neutrophils were 
seen after 6 days. Crypt cell death was also observed on days 7 to 12 posttrans-
plant, but it never became a prominent feature. Fibrin thrombi in mucosal 
capillaries were observed with increasing frequency during the course of graft 
rejection. This was associated with extensive necrosis of the mucosa at 11 and 12 
days after grafting. Widespread thrombosis, resulting in ischaemia, is probably 
the principal cause of graft necrosis. Mononuclear cells accumulated around 
blood vessels in the mesentery. Eleven to 12 days posttransplant, early changes 
in the arteries were endothelial hypertrophy, and this was followed by mild 
intimal proliferation and thrombosis. 
The mesenteric lymph node became rapidly depleted of lymphocytes, which were 
replaced by large mononuclear cells, presumably macrophages, and increasing 
numbers of fibroblasts. 
IMMUNOSUPPRESSION WITH CYCLOSPORINE 
Before CsA became available, other means of immunosuppression were used in 
attempts to prolong small bowel allograft survival. Taylor et al. (1966) used high 
doses of azathioprine in the artificial model of transplantation of a small 
segment of small bowel as a Thiry-Vella fistula in the neck of dogs. Only 
marginal prolongation of graft survival was found. Preston et a!. (1966), using the 
same model, added prednisone to azathioprine and found prolongation of graft 
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survival from 9 to 27.5 days. Addition of anti-lymphocyte serum (ALS) to this 
regimen prolonged graft survival to a mean of 38 days (Hardy et al. 1970). 
Interest in SBT has rekindled since the introduction of the potent immuno-
suppressant CsA (Kirkman, 1984). Reznick et al. (1982) first reported graft 
survival to be prolonged to a mean of 90.6 days after intramuscular (i.m.) 
administration of 25 mgjkg/ day. Many dogs died from pneumonia. perhaps due 
to the malnourishment caused by chronic rejection of the grafts, or due to this 
high dose CsA Discouraging results in both dogs and pigs have also been 
reported by others (Pritchard & Kirkman 1985). 
In both unidirectional and in fully-allogeneic rat models CsA is able to signifi-
cantly prolong small bowel allograft survival (Schraut, 1988). This is highly 
dependent on the rat-strain combination used. We have shown that in the BN to 
WAG rat donor-host combination long-term allograft survival is easy to achieve 
using short courses of CsA, whereas in the reverse WAG to BN model CsA has 
only a lintited efficacy in prolonging graft survival (de Bruin et al. 1990"). In 
unidirectional P to F1-hybrid models CsA appears to be less effective in 
preventing GVHD (Kirkman, 1984). 
In large animal models prolongation of graft survival is hard to achieve, but 
continuous intravenous (i.v.) infusion of CsA has been shown to result in long-
term allograft survival in pigs, which survived for 122:t33 days, without animals 
that died from rejection (Grant et al. 1988). These results were achieved with 15 
mgjkg CsA given intravenously for 7 to 10 days, followed by 30 mg/kg/day 
orally, tapered to 15 mg/kg over 3 to 4 months. However, high CsA blood levels 
of approximately 600-700 ng/ml were measured which could lead to toxicity on 
the kidney (English et al. 1987) and bowel (Crane et al. 1990), and to an 
unacceptable high risk of developing malignancies (Penn, 1991). Recently, 
Meijssen et al. (1992') reported that graft rejection in dogs can be prevented 
with CsA when donor and recipient are fully MHC-matched. CsA dosages in this 
group were 15 mgjkg i.m. from 1 day before surgery until the end of the frrst 
postoperative week, and 30 mgjkgj day orally until day 200 posttransplant 
thereafter. Recipients of an MHC-matched graft survived for a mean of 211 days 
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without signs of rejection during CsA therapy. MHC-rnismatched dogs survived a 
mean of 113 days with 4 of 6 animals showing rejection that occurred during 
CsA treatment. 
Pretransplant CsA treatment (pretreatment) of the recipient is associated with a 
reduced incidence of acute rejection in kidney transplantation (Hong et a!. 
1991). Moreover, Kahan et a!. (1984) and Rogerson et a!. (1986) found that low 
plasma CsA levels in the early postoperative period are associated with a higher 
incidence of rejection following human renal transplantation. However, in an 
experimental rat study we were unable to significantly prolong small bowel 
allograft survival after preloading the recipient with high dose CsA, as compared 
to postoperative immunosuppression only. although no acute rejection occurred 
(de Bruin et al. this thesis). It is generally thought that oral administration of 
CsA should be avoided (Kirkman, 1984), since the disrupted lymphatics of the 
graft are unable to transport this lipophilic drug to the blood. Although we have 
shown that absorption of orally administered CsA after total small bowel 
resection is severely impaired (de Bruin et al. 1992'), we found no lowered 
plasma through levels in the first week posttransplant. This finding is consistent 
with observations by Aeder et al. (1984) and LaRosa et al. (1989'), who found 
that oral and intraluminal CsA absorption within one week after transplantation 
did not differ significantly from preoperative or control values. This indicates 
that there must be an alternative mechanism by which CsA is delivered to the 
blood. By administering CsA intraperitoneally in normal dogs, Cohen et a!. 
(1983) have shown that some absorption may take place via the peritoneum. It is 
possible that after transplantation CsA in the lymph leaks into the peritoneal 
cavity through the disrupted lymphatics, and is subsequently reabsorbed. So even 
before lymph vessel continuity is reestablished 4 to 10 weeks posttransplant, as is 
shown to happen in different models (Kocandrle et al. 1966, Rotman et al. 1986, 
Schmid et al. 1990), orally given CsA is absorbed. It was shown, however, that 
CsA absorption is highly variable and unpredictable during the early 
postoperative period, and, moreover, rejection can impair the ability of the graft 
to absorb CsA (Cohen et al. 1983). Therefore it seems justified to advocate the 
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parenteral administration as main route, especially in the first months after 
transplantation. Whether concomitant oral treatment can be of benefit due to 
local immunosuppressive effects needs to be investigated. 
OTHER FORMS OF IMMUNOSUPPRESSION 
FK-506 and Rapamycin (RAPA) are both macrolides produced by Streptomyces 
species, with potent immunosuppressive activity (Chang et al. 1991). FK-506, like 
CsA, counteracts mitogenic or antigenic stimulation at an early stage of T-cell 
activation, whereas RAP A intervenes in events more closely related to DNA 
synthesis. All 3 drugs exert their action via a class of binding proteins known as 
immunophilins, which possess cis-trans peptidyl prolyl isomerase activity. There 
is evidence that FK-506 and RAPA bind to the same binding site, whereas CsA 
binds to the sintilar, but nonidentical cyclophilin. Probably as a result of this, 
RAPA has been shown to antagonize the FK-506 induced inhibition ofT-cell 
proliferation, and FK-506 has been shown to antagonize the action of RAPA, 
although potentation of either drugs may be achieved using equimolar concen-
trations of the 2 agents. Combinations of CsA and FK-506 or RAPA invariably 
result in a greater inhibition of mitogen and alloantigen-induced T-cell respon-
ses. 
RAPA suppresses a wider spectrum ofT- and B cell activation pathways than 
FK-506 or CsA Interest in these 2 agents for use in SBT is a direct result of the 
potency of RAPA and FK-506 in prolonging graft survival (Thomson et al. 1990). 
FK-506. 
Hoffman et al. (1990) performed an extensive study on the use of FK-506 for 
SBT in rats (Table 2). They showed that long courses of FK-506 are more 
effective than CsA in the prevention of acute rejection and lethal GVHD in 
semi-allogeneic models. Short courses of 2 mg/kg on days 0 to 6 posttransplant 
prevented rejection in the fully-allogeneic ACI to Lew model. In the model used, 
a 20-fold higher dose of CsA was needed to obtain comparable survival times. 
No clinical GVHD was observed. Using the BN to Lew rat model, Lee et al 
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(1990) found similar results, while Stangl et al. (1991) showed in the same model 
that FK-506 is able to reverse an ongoing chronic rejection process. We were 
unable to find superior immunosuppressive effects of short-course FK-506 over 
CsA using the fully-allogeneic WAG to BN rat-strain combination (de Bruin et 
al. 1991). Moreover, after FK-506 treatment severe GVHD was seen. This was 
also observed by Murase et al. (19913 ) in the BN to Lew combination giving 0.15 
mg/kg for 14 days. Hatazawa et al. (1992), on the other hand, observed 
prolonged survival administering 1 mg/kgjday for 8 weeks in the same modeL 
Masutani eta!. (1992) found in a P to F1-hybrid model, that 14 days after HSBT 
using 0.32 mg/kg/day FK-506 animals showed no histologic signs of GVHD, and 
Markus et al. (1991) showed that FK-506 is able to reverse ongoing GVHD after 
bone-marrow transplantation better than CsA and RAP A 
Rapamycin. 
Continuous i.v. administration of 0.80 mg/kg of RAPA for 14 days was shown to 
significantly prolong allograft survival (Strepkowski et aL 1991). Using Lew and 
(LBN)F1-hybrid one-way models they showed that RAP A is able to suppress 
both isolated rejection and GVHD, although its effect on GVHD is less potent 
than on rejection (Kahan et aL 1991). Chen et aL (1992) however found RAPA 
to be equipotent in suppressing isolated rejection and GVHD in the same 
modeL They also showed that RAP A is synergistically effective with CsA Similar 
immunosuppressive efficacy as with CsA was achieved with a 5-fold lower dose 
of RAPA after fully-allogeneic rat-SBT (Strepkowski et aL 1991). No toxicity was 
reported from these studies. 
Both FK-506 and RAPA may prove to be the more potent, less-toxic immuno-
suppressants needed for successful clinical SBT, but this has to be evaluated 
clinically. 
IMMUNOMODULATION 
It has been widely recognized that preconditioning of the recipient with donor-
specific blood transfusions (DST) may lead to prolongation of allograft survival 
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in both experimental (Marquet et a!. 1971) and clinical (Opelz et a!. 1976) 
transplantation. 1n the BN to WAG rat donor-host combination, DST are very 
effective in prolonging heart and kidney graft survival (Marque! et a!. 1971). 
However, 3 pretransplant DST had no effect on total or segmental SBT in this 
model. When DST was combined with low-dose CsA administation, no additio-
nal prolongation of graft survival could be measured (de Brnin et a!. 1990b). 
Similar results were reported by Fecteau et a!. (1992). In contrast, Martinelli et 
a!. (1989) did find a synergistic effect of CsA and DST, and with FK-506, DST 
acts synergistically as well (Fukuzawa et al. 1991). 
These findings indicate that DST may contribute to the prevention of rejection, 
but more studies are needed to determine whether DST can be a therapeutic 
option in living-related SBT. 
GRAFT-VERSUS-HOST DISEASE AFfER SMALL BOWEL TRANSPLAN-
TATION 
Monchik & Russel (1971) first showed that transplantation of the small bowel 
may produce a lethal GVHD in parent to Fl-hybrid rat models. This GVHD 
shows histologic similarities to that induced by bone-marrow transplantation 
(MUller-Hermelink & Deitz 1986), and is caused by T-lymphocytes originating 
from the transplanted gut and its mesenteric lymph nodes (Kirkman et a!. 1984b, 
Wallander et al. 1989). Clinically, it is characterized by dermatitis, alopecia, a 
hunched posture, and eventually death of the animal. Observations in these 
unidirectional GVHD or rejection models are of uncertain relevance to the 
clinical situation, in which a two-way reaction between rejection and GVHD may 
occur (Kirkman, 1984). In fully-allogeneic small bowel transplantation, rejection 
rather than GVHD seems to predominate (Monchik & Russel 1971, Lee & 
Schraut 1986b, Frantz et al. 1988). In some fully-allogeneic models, 30 to 50% of 
the animals show clinically overt GVHD, distinguished from that in the one-way 
model by its non-lethal, short-lived transient nature. Little is koown of the 
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Table 2: Use of f'K.SQ6 in rat small bowel transplantation. 
Author Model1 FK-506 dose Additional SurvivaP GVHD 
mgfkg treatment/remarks da" 
Hoffmann et al. 1990 HSBT-pc 2,mgfkg, d 3-Q 34.9:::30.8 none 
2,mg/kg. d 3-6 + 50.6:::46.5 none 
1 mg/kg, d S..30, qod 
one-way rejection 83.0:::82.6 none 
one-way GVHD 188.0:::72.1 125% 
Lee et a1. 1990 OSIIT 2 mgjkg. d 04 >180 none 
de Bruin et a!. 1991 OSBT-pc 2 mgjkg. d 0,1,2.4,6 28.5:::6.8se -~ 
2 mgjkg. d 0,1,2,4,6 5 Gy donorirr 31.1:::5.7se none 
Fukuzawa ct a!. 1991 HSBT-pc 0.3 mgfkg, d 0-14 1.0 mgjkg. d -8-4 9.8::!:2.8 
"' 0.3 mgjkg. d 0-14 1.0 mg/kg, d -S-4 
+ DSf, d..g3 
62.2:::33.6 
"' 
Murase ct a!. 1991a OSBT-pp 0.15 mgjkg, d 0-13 445 median mild, self Iimiting4 
0.15 mgjkg. d 0-13 "20-30 days" '""'~ 
Murase et aL 1991b OSBT-pc 0.64 mg/kg. d 0-13 121. median none 
Santiago et a!. 1991 HSBT-pc 0.3 mgjkg. d 0-13 6.8:::0.8 n' 
1.0 mg/kg. d 0-13 12.4:::8.4 m 
2.0 mg/kg. d 0-13 17.4:::4.7 n' 
0.3 mgfkg. d 0-13 donor 2 41.2:::3.8 
"' mgjkg FK. d -3,-2.-1 
none donor 2 12.2:::1.9 
mgjkg FK. d -3,-2,-1 
Tadeka et aL 1991 HSIIT 0.32 mgfkg. d 0-13 minor HC incomp. 80% > 175 ., 
0.32 mgfk:g. d 0-13 major HC incomp. 38.0:.':6.3 ., 
Hatazawa et ai. 1992 OSBT 1.0 mgjkg/d, 8 weeks, s.c. ~>s weeks" none 
Stangl et a!. 1992 ., 10 mgfkg CsA, d 0-5 27.3:.':4.8 
10 mgjkg OiA. d 0-S FK-506, 2 mgfkg, >Z70 none 
d 13-15 
Utsunomiya et al. OSBT-pc 0.1 mgjkg, d 0-29 13.4:.': 3.07 ., 
1992 03 mgjkg, d 0-29 34.6:.':12.79 ., 
05 mgjkg, d 0-29 32.6:.-:26.16 ., 
Yamataka et al. 1992 M 1.0 mgfkg, d 3-5, i.p. ">20" ., 
1.0 mgfkg. d 3-5, i.p., ">20" ., 
+ a:-ICAM-1. 1 mgjkg, d 1-3 
1: Fully allogeneic model, unless otherwise stated. OSBT: orthotopic, HSBT: heterotopic small bowel transplantation, 
pc: porto-caval venous drainage, pp: porto-portal venous drainage. 
nr: not reported. FK was administered intramuscularly, unless otherwise stated. 
2: Mean survival in days, unless indicated otherwise. 
3: osr + donor-specific blood transfusion. 
4: Murase et al. 1991: mild. self limiting GVHD in BN to Lew combination, severe GVHD in Lew to BN combination. 
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interaction between rejection and GVHD in these models. 
Cohen et al (1976) investigated the effect of graft-irradiation with 0.5 and 1.5 
Gy prior to transplantation in a canine small bowel allograft modeL They found 
that pretreatment with 1.5 Gy leads to rejection of the small bowel allografts in 
9.2 days. Pretreatment with 0.5 Gy, however, prolonged graft survival to a mean 
of 28 days. Therefore they hypothetized that there is a balance between rejection 
and GVHD, and that the development of subclinical GVHD after 0.5 Gy 
irradiation results in prolonged graft survival. 
Since the early 1960s it bas been known that GVHD depresses the host's 
immunological reactivity (Howard & Woodruff 1961). This is best shown by 
clinical results obtained with T-cell depleted bone-marrow transplantation. On 
the one hand, T-cell depletion significantly reduces acute GVHD, on the other 
hand it substantially increases graft rejection (Storb, 1989). GVHD is also known 
to be immunosuppressive after experimental spleen-cell-, and small bowel 
transplantation (Grant et al. 1989). 
Histopathologically, GVHD is characterized by a loss of the normal architecture 
of the spleen, lymph nodes, and thymus (Deitz et al. 1981, Schraut et aL 1986, 
Grant et al. 1989). This leads to profound immunosuppression with impaired 
humoral and cell-mediated immune responses (Grant et al. 1989). This immuno-
suppression probably accounts for the observed in vivo balance between rejecti-
on and GVHD. 
Diflo et al. (1989) observed a short, sublethal GVHD approximately 4 to 6 
weeks after fully-allogeneic transplantation in immunosuppressed animals. 
Donor-pretreatment with ALS completely eliminated GVHD, but had no effect 
on graft survival in these immunosuppressed hosts. Gundlach et al. (1989) found 
that mesenteric lymphadenectomy, a method which has been shown to eliminate 
GVHD (Pirenne et al. 1990), does not influence the course of acute graft 
rejection in non-immunosuppressed recipients. CsA was not effective in preven-
ting chronic rejection following mesenteric lymphadenectomy, whereas the same 
dosage of CsA fully prevented rejection of normal small bowel grafts. They 
suggested that the absence of an immunosuppressive effect caused by a GVH-
22 
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reaction had led to chronic rejection in this model. 
We showed that irradiation of the donor with 10 Gy one day before fully-
allogeneic SBT in the WAG to BN rat model completely eliminated GVHD, and 
significantly shortened survival times (Saat et al. 1989). Moreover, CsA treat-
ment of the recipient was unable to completely override this effect (Saat et al. 
1991). Pretreatment of the donor with ALS also eliminated clinical GVHD, and 
led to significantly accelerated rejection (de Bruin et al. 1992b). When our 
recipients of a graft pretreated with AlS received immunosuppressive treatment 
with CsA no adverse effect on graft survival was seen anymore, whereas clinical 
GVHD remained suppressed. This important finding is in accordance with 
earlier findings from our laboratory (Saat eta!. 1991). The usefulness of manipu-
lation of this balance for future clinical SBT remains to be established, since it is 
unclear yet whether this balance theory is a rat strain dependent phenomenon, 
and even whether GVHD will be a clinical problem. 
Prevention of GVHD in SBT often implies reduced immunogenicity of the graft 
also. In attempts to control both rejection and GVHD, reduction of the immun-
ogenicity, and consequently a diminishing of the number of leukocytes in the 
graft has been carried out. Moreover, in the recipient the immunosuppression 
used to prevent rejection also suppresses GVHD, although in semi-allogeneic rat 
models CsA appears to be less effective in preventing GVHD than it prevents 
rejection. FK-506 may even enhance GVHD (de Bruin et al. 1991, Murase eta!. 
1991'). 
Several donor-pretreatment modalities have been shown to abrogate or diminish 
clinical GVHD following experimental SBT. Total body irradiation of the donor 
prior to transplantation completely eliminates GVHD (Monchik & Russel 1971, 
Lee & Schraut 1985, Deitz et a!. 1986) and so does pretreatment of the donor 
with ALS (Shaffer et al. 1988), mesenteric lymphadenectomy (Deitz et al. 1986), 
and reduction of the length of the graft (Kimura et al. 1987). 
High levels of the cytokine tumor necrosis factor-alpha (TNFa) are measured in 
rats with lethal GVHD after SBT in a P to F1 GVHD model (Pirenne & Dunn 
1991). Blocking of TNFa activity reduces the mortality of GVHD after experi-
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mental bone-marrow transplantation, and prevents skin and gut lesions of 
GVHD (Piguet et al. 1987). This suggests that anti-TNFe< antibody therapy could 
be helpful in reducing the severity or lethality of GVHD. Other cytokines may 
also be involved in the pathogenesis of GVHD (Mowat, 1989), and are impor-
tant in graft rejection as well. Anti-cytokine therapy might therefore prove to be 
valuable in concert with other immunosuppressive modalities. 
GRAFT PHl{SIOLOGY 
The small bowel exhibits nutritional, motor, hormonal and immunologic functi-
ons. After transplantation, changes in these functions may be expected for 
several reasons: the ischaemia, lymphatic disruption, and denervation caused by 
the transplant procedure, the immunological processes arising after allogeneic 
transplantation, and the immunosuppressive drugs given. The small bowel 
transplant must be able to overcome the symptoms of short bowel syndrome . .In 
the adult recipient, long-term prevention of malnutrition and in children normal 
growth and development followed by long-term prevention of malnutrition are 
prerequisites for successful clinical small bowel transplantation. 
Nutritional function. 
A sensitive functional test is whether a small bowel transplant recipient is able to 
grow and develop normally. Several studies have shown that rats are able to gain 
weight normally after allogeneic total SBT (Schraut et al. 1987, de Bruin et al. 
1992'). However, rats grafted with a segmental small bowel transplant may 
develop impaired nutritional parameters (Schraut et al. 1987), or grow subopti-
mally (Oki et al. 1989, de Bruin et al. 1992'), although Kirsch et al. (1991) have 
shown that there were no significant differences in growth between sham 
operated rats, animals with 50% of their bowel Gejunum) intact, and animals 
transplanted orthotopically with 50% of their total bowel length of jejunum 150 
days posttransplant. Moreover, just as the native gut after bowel resection, the 
transplanted intestine is also capable of adaptation (i.e. increased bowel diame-
ter and increased villus height) (Kirsch et al. 1991). In dogs, conflicting data 
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have been reported. Long-term surviving allografted dogs maintain their preope-
rative body weight, but have only slightly better nutritional parameters than dogs 
with short gut syndrome (Diliz-Perez eta!. 1984). Weight after transplantation of 
a 100-cm long segmental ileal allograft was maintained at 88% of their preopera-
tive weight (Collin et a!. 1987). Autotransplanted dogs attained their preoperati-
ve weight not until 1 year after transplantation (Raju et a!. 1989). Moreover, 
Ballinger et a!. (1962) reported that substantial nutritional disturbances can be 
expected from lymphatic and neural division alone. Recently it was shown that 
autotransplanted adult dogs regain their preoperative weight within 1 year after 
transplantation. One year posttransplant, these animals still had elevated stool 
moisture content, and developed steatorrhea and impaired D-xylose absorption 
(Thompson et a!. 1992). However, MHC-matched, CsA treated recipients of a 
45-65 em ( ±25% of total length) long allograft of terminal ileum did not differ 
in growth or fecal fat content from sham-operated controls, indicating adequate 
nutritional function (Meijssen et a!. manuscript in preparation). In young pigs, 
total small bowel allografts are able to adequately sustain the recipients' growth 
at a rate comparable to normal controls (Grant et a!. 1988). Porcine segmental 
jejunal allografts comprizing approximately 25% of the smaii bowel length are 
incapable of doing the same; by 180 days after transplantation animals had 
increased their weight by only 40% (Kimura et a!. 1990) as compared to more 
than 100% in 4 weeks in Grants' animals. From these studies it seems that, from 
a nutritional point of view, allotransplantation will be possible. Taking into 
account its limitations (living-related donation, abdominal size), as much bowel 
length as possible should be transplanted. More studies are needed to determine 
whether long-term functioning of SBT is feasible in both juvenile and adult 
recipients as opposed to long-term total parenteral nutrition, and how compromi-
zed functions may be restored. 
Immune function. 
The gut mucosa has an important barrier function to luminal food antigens and 
pathogens (reviewed by Brandtzaeg et a!. 1989). It is constantly chaiienged by 
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microbial and food antigens, and its responses to these stimuli must be appropri-
ate; infections must be limited but at the same time the integrity of the vulnera-
ble mucosa must not be compromized. Intestinal immunity was first observed 
when protective "coproantibodies" were found in stools of orally immunized 
rabbits. However, the vulnerable gut mucosa should also be protected against 
potentially harmful reactions against harmless antigens. Indeed, suppressive 
mechanisms after immunisation with harmless antigens have been observed, and 
are called "oral tolerance" (Tomasi, 1983). How the suppressive and inductive 
immunoregulatory mechanisms are established in the intestine is still obscure. 
The secretory immunoglobulin (Ig) system is the major effector mechanism of 
mucosal immunity. Approximately 70-80% of all Ig is produced by B-lymphocytes 
in the mucosa of the small and large boweL This secretory Ig, which is mainly 
IgA, is transported to the gut lumen through the epithelial cells of the crypts of 
lieberkuhn. 
Numerous T-lymphocytes are localized in the gut epithelium. In contrast to the 
lamina propria T-lymphocytes, these intra-epithelial lymphocytes (IEL) are in 
direct line with macromolecules in transit across the epithelium (Ernst et a!. 
1985). Their function is still obscure, but they are thought to play a role in 
cytotoxic as well as suppressive immune reactions. Apart from these solitary 
cells, the gut also contains organized solitary lymph nodes, and lymph node 
aggregates: Peyer's patches. These are probably the major site of antigen 
presentation and commitment to slgA syothesis in the mucosal-associated-
lymphoid-tissue. Sensitized and committed cells migrate via the mesenteric 
lymph node and the bloodstream to distant gut. lgA producing cells may also 
migrate to other mucosal surfaces that are part of the mucosal-associated-
lymphoid-tissue, such as the lung, mammary glands, salivary- and lacrimal glands 
(Tomasi, 1983). 
The immune function of bowel transplants is largely unknown. Both in man 
(lwaki et a!. 1991) and in experimental animals (Lear et a!. 1989) it was found 
that graft-lymphocytes are replaced by cells of recipient origin without the 
occurrence of rejection. Xia & Kirkman (1990') found no differences in graft 
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total sigA production after syngeneic and semi-allogeneic SBT in rats. Im-
munosuppression with CsA had no effect on the total sigA production. However, 
allografted animals treated with CsA failed to produce significant amounts of 
specific anti-cholera toxin sigA when challenged with choleratoxin at the time of 
transplantation. The specific immune response against cholera toxin remained 
completely suppressed as long as the animals received CsA (Xia & Kirkman 
1991). When allografted animals were boosted with choleratoxin 7 days post-
transplant, after having been primed 1 week before transplantation, normal sigA 
levels were measured (Xia & Kirkman 1990"). The presence of (part of) the 
recipient's colon could be important since it also contributes to gut mucosal 
immunology. The effect of different immunosuppressive agents on graft immune 
function needs to be investigated. 
Motor function. 
The motility of the normal, intact upper gut has been well characterized. The 
stomach and small intestine display distinct patterns of motility during fasting 
and feeding. During the fasting or interdigestive period, the upper gut shows a 
spontaneous and recurrent cyclic pattern of motility, called the migrating motor 
complex (MMC) or interdigestive myoelectric complex. Feeding interrupts this 
MMC and induces a less well-defined, none-cyclic pattern of intermittent, low 
amplitude contractions that persist for a variable period of time dependent on 
the type and amount of nutrient. These motor patterns are physiologically 
important. During fasting, the MMC sweeps non-digestable intraluminal debris 
from the stomach and small intestine ("intestinal housekeeper"). The change in 
motor pattern caused by feeding is believed to maximize mixing of food and 
facilitate its absorption. 
Schiller et a!. (1973) noted alterations in the motility of jejunal segments 
transplanted in the neck of recipient dogs. In Lew rats that had received a 
segmental syngeneic SBT, basal electrical rhythm of the graft was not observed 
for approximately 2 days after transplantation, and did not attain the level of 
normal rats for at least 3 weeks. MMC were not observed in the transplanted 
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segment until postoperative day 11, and was constant from postoperative day 16 
(Vane et a!. 1989). In a dog model of small bowel autotransplantation, in which 
all extrinsic neural and lymphatic connections to the jejunoileum were transec-
ted, the MMC was present, although the coordination between the innervated 
duodenum and the denervated jejunoileum, present in the normal gut, was 
lacking (Sarr et a!. 1989). The presence of MMC is of importance since its 
intestinal housekeeper function is thought to be essential in preventing bacterial 
overgrowth, a situation also encountered after SBT (see below). Feeding or 
infusing the putative postprandial peptide hormones cholecystokinin or pentagas-
trin induced a normal "fed" pattern of contractions (Sarr et al. 1989). This 
implies that the intrinsic nerves of the gut are capable of generating these motor 
patterns without imput from the central nervous system. 
Hormonal function. 
A number of hormones are produced by cells scattered diffusely throughout the 
length of the gut. The physiological role of these peptides is still being evaluated. 
Intraluntinallevels of vasoactive intestinal peptide, somatostatin, and substance P 
are stable from 4 days after syngeneic SBT to 1 year posttransplant. During 
rejection, however, lowered levels of these hormones were found (Teitelbaum et 
a!. 1989). LaRosa et al. (1989') reported that SBT does not alter the baseline 
levels, nor the response to stimuli of serotonin and substance P. 
MONITORING OF GRAFT REJECTION 
Unlike renal, hepatic, and pancreas grafts, intestinal grafts have as yet no 
specific distinguishing serum markers to diagnose rejection. Histology remains 
the gold standard for diagnosis of rejection (Meijssen eta!. 1991"), although this 
method has several shortcomings. Full-thickness biopsies from the graft have to 
be taken from cutaneous stomas to reliably recognize rejection (Millard et a!. 
1986), which involves the risk of graft perforation. Multiple biopsies are necessa-
ry because rejection shows a patchy character and may be easily missed (De-
nnison et al. 1987, Schmid et al. 1989, Meijssen et al. 1991°). In view of these 
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limitatioll5 several small bowel function tests have been studied to determine 
their usefulness as marker for rejection. Function tests of the graft which need 
biopsy material from the graft, snch as determination of brush border enzyme 
activity (Schroeder et a!. 1990", Meijssen et a!. 1992b) have the same disadvanta-
ge of dependence on the presence of an enterostoma. Moreover, they do not 
detect rejection at an earlier stage than does histology. Functional tests, functi-
onal absorption tests, and putative serum markers of rejection must at least be 
as sell5itive and as specific as histology in order to be coll5idered an alternative 
for histology. 
In order to be absorbed, the disaccharide maltose must be split into glucose by 
the brush border enzyme maltase. This glucose is subsequently absorbed and 
raises the blood glucose leveL In this way, the maltose absorption test can he 
performed as a glucose tolerance test. Billiar eta!. (1984) studied this test in rats 
and found that a reduction in maltose absorption preceeded histologic changes 
by 1 to 2 days. They concluded that this test is a reliable, reproducible, and 
sensitive method to monitor rejection. 
Intestinal absorption of water, sodium, glucose, alanine, and lauric acid have also 
been proposed as early serum markers. These substances require active trall5pon 
by the mucosa, and significant decreases in their absorption were found when the 
first changes in histology were present (Dennison et a!. 1987). 
Intestinal permeability to 51Cr-EDTA is increased during rejection. In rats, a 2-
fold increase was measured at the time when minimal histologic signs of rejecti· 
on were present (Grant et al. 1991b). Assessment of urinary 51Cr-EDTA as 
measure for intestinal permeability has already proved its usefulness permitting 
early detection and treatment of an acute rejection episode after clinical small 
bowel-liver transplantation (Grant et al. 1990). 
Monocyte-macrophage procoagulant activity is a measure of immune activation 
of mononuclear cells. Measured in peripheral blood mononuclear cells, elevated 
levels were observed before histologic changes of allograft rejection, and 
remained high throughout the course of rejection. This test appears to be an 
accurate serum marker for detection of rejection (Silverman et a!. 1987, Kim et 
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a!. 1990). 
The lysosomal acid hydrolase N-acetyl hexosaminidase (NAH) is elevated in 
serum in association with intestinal ischemia. A study performed in rats sugge-
sted that determination of serum NAH is a simple and rapid test which could 
prove useful as serum marker for small bowel allograft rejection (Maeda et al. 
1987). In contrast to this report, Meijssen et al. (1991') found in a dog model 
that a significant rise in NAH occurred after histologic changes related to acute 
rejection were visible. 
Transepithelial potential difference has been studied to determine its value as 
diagnostic tool for early detection of rejection. Madara & Kirkman (1985), using 
an in vitro method, found that a decreased spontaneous transepithelial potential 
difference, which is an index of baseline active transport resulting from electrow 
genic sodium absorption and chloride secretion, correlated with histologic signs 
of rejection. Sodium-coupled glucose absorption, which is an index of villus 
function, and theophylline-stimulated chloride secretion, which mainly measures 
crypt cell function, decreased when structural changes indicative of rejection 
became apparent. Lee et al. (1989) found that changes in basal transepithelial 
potential difference parallelled, and often preceded histological changes of 
rejection. Because of the invasive nature of their method, they did not consider it 
a practical clinical tool. In a model of canine small bowel autotransplantation 
Meijssen et al. (1991a) developed a non-invasive method using a double balloon 
catheter which was inserted in an enterostomy, and isolated a loop of bowel in 
which electrophysiological measurements could be performed. It was shown that 
in vivo electrophysiological parameters provide a useful tool in the assessment of 
small bowel autotransplants. Reduction of transepithelial potential difference 
preceded degenerative mucosal changes in the graft. It was subsequently found 
that, following allotransplantation, electrophysiological parameters correlate with 
histologic alterations of acute rejection, thus demonstrating that serial monitoring 
of transepithelial potential differences is a noninvasive method for detecting 
small bowel allograft rejection that circumvents the disadvantages of histologic 
monitoring (Meijssen et al. 1991b). 
30 
General introduction 
SMALL BOWEL TRANSPLANTATION IN MAN 
Before CsA became available, attempts at clinical SBT invariably were unsuc-
cessful. Failures were due to technical complications, rejection, GVHD, and 
sepsis (reviewed in Kirkman, 1984). These discouraging results, and the availabi-
lity of TPN, led to a diminished interest in SBT. 
Several successful SBT have been reported since CsA was introduced. Deitz et 
a!. (1989), reported a case of successful SBT using a segment of 60 em of 
jejunum and ileum harvested from the sister of the recipient. Although this graft 
was not rejected, the patient had severe diarrhea The graft donor also develo-
ped chronic diarrhea Nine attemps of SBT in 7 children have resulted in 1 
successful case in which the recipient is alive for more than 3 years after 
grafting. In all other patients the grafts had to be removed because of necrosis or 
rejection was uncontrollable (Goulet et a!. 1990). The combined European 
experience in SBT has been reported recently by Schroeder et a!. (1990-'); from 
March 1987 until July 1990, 15 SBT were performed in 12 patients. Four grafts 
are functioning, with patients being independent of TPN. Immunosuppression in 
these patients was with CsA and prednisone, usually supplemented with azathio-
prine and ALS. In one patient transient GVHD was encountered. Recently a 
successful case of multi-organ transplantation including liver, pancreas, stomach, 
and small bowel, was reported by Margreiter et aL (1992). Two minor rejection 
episodes of the bowel were encountered. Six months postoperatively all grafted 
organs functioned normally. 
McAllister et aL (1992) performed isolated SBT as well as combined small 
bowel-liver transplantation and abdominal cluster transplantation; the isolated 
small bowel transplant had to be removed 15 days posttransplant because of 
uncontrollable rejection. Two of 3 patients with small bowel-liver transplantation 
are alive on CsA therapy, whereas the other died from a non-immunological 
cause. One of 2 patients given an abdominal cluster transplant 1 is well 7 months 
postoperatively whereas the other has died of a lymphoma Todo et a!. (1992) 
reported on 1 successful isolated SBT and 4 small bowel-liver transplantations 
using FK-506 as main immunosuppressant. The function of the transplanted 
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intestine alone or with accompanying liver has been satisfactory in all 5 patients. 
Altbough alimentation was slowly achieved, all patients eventually became 
completely independent of TPN, and maintained, or gained weight. 
In all clinical cases, intestinal continuity was restored in stages. At the first 
operation, tbe proximal and distal ends, or the distal end of the graft only, were 
brought out as enterostomies. This allowed for macroscopic inspection and graft 
biopsy for monitoring graft rejection. Moreover, early alimentation of the graft 
or decompression in case of ileus are Possible. In a second operation some 
weeks later intestinal continuity was restored, after which oral feedings could be 
instituted (Deitz et al. 1989, Grant et a!. 1990, Todo et a!. 1992). 
Although in most cases reported the postoperative course was stormy, these 
successful cases suggest that SBT has become a clinical reality. 
FUTURE PROSPECTS 
The reasons why the small bowel graft is particularly vulnerable to rejection are 
now being delineated. The high rate of sepsis after SBT (Schroeder et a!. 1990", 
Grant et al.1991 b) has several causes: immunosuppression given to the recipient 
compromises the immunologic barrier function of the bowel wall. Ischemia and 
rejection increase the permeability of the graft by compromising the physical 
barrier. This has been shown to lead to bacterial translocation to the host (Grant 
et al. 1991b, Browne et a!. 1992). Leakage of toxins also occurs in this phase. 
This may be aggravated by the bacterial overgrowth in the graft encountered 
after SBT (Browne et a!. 1992, Thompson et al. 1992). 
Measures maintaining the gut barrier function after SBT will improve its 
outcome. Better immunosuppressive drugs like RAP A may have a higher 
therapeutic index than CsA, although some believe that CsA as mainstay of 
immunosuppressive therapy will provide satisfactory immunosuppression 
(Schroeder et al. 1990", Margreiter et al. 1992). 
Several authors suggest an advantage of combined small bowel-liver transplanta-
tion, which is nourished by the successful clinical small bowel-liver transplantati-
on (Grant et al. 1990). In rats, SBT performed 17 days following orthotopic liver 
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transplantation led to long-term survival of the small bowel graft without any 
immunosuppression, whereas isolated small bowel grafts were rejected in 6 to 9 
days (Sarnacki et al. 1992). Similar results were reported by Zhong et al. (1991). 
However, since not all patients that are candidate for a SBT need a liver graft, it 
is important to elucidate the mechanism by which the liver "protects" the SB 
fro:u rejection, and to assess whether the same results may be obtained with an 
auxilliary liver graft. 
Early institution of feeding of the graft helps preventing disuse atrophy (Levine 
et al. 1974, Riecken et al. 1989), and antibiotics reduce the bacterial load of the 
gut. Options that bear an experimental character include administration of 
hormones trophic to the gut such as epidermal growth factor and prostaglandin 
13, or the use of nutrients that are essential to the gut. One such nutrient that, in 
our opinion, deserves special attention is the amino acid L-glutamine. Several 
studies have demonstrated that glutamine is the principal fuel for enterocytes 
(Windmueller, 1982, Souba et al. 1990"). There is only limited evidence that 
glutamine is essential for maintenance of normal intestinal function (Souba et al. 
1990"). However, the stress of a major operative procedure combined with 
general anaesthesia is followed by a fall in circulating and muscle glutamine 
concentrations (Souba & Wilmore 1983). During injury or stress glutamine may 
be a necessary dietary component to maintain gut structure and function. This is 
possibly due to the fact that glutamine is essential for nucleic acid biosynthesis 
and might be especially important during critical illness when the mucosal 
barrier becomes susceptible to breakdown (Souba et al. 1990"). It has been 
shown, for instance, that glutamine consumption by the intestinal tract is incre-
ased by 75% after laparotomy (Souba et al. 1990'). It has also been shown that 
glutamine reduces bacterial translocation from the gut to the mesenteric lymph 
nodes following abdominal irradiation (Souba et al. 1990"). Moreover, glutamine 
supplementation of standard TPN solutions decreases the villous atrophy associa-
ted with long-term i.v. feeding (O'Dwyer et al. 1989), and bacterial translocation 
following TPN administration is attenuated when glutamine is added to the 
mixture. This diminished translocation was associated with a normalization of 
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sigA levels and a decrease in bacterial adherence to enterocytes, suggesting that 
glutamine added to the 1PN solution enhances gut immune function (Burke et 
a!. 1989, Alverdy et a!. 1992). Preliminary results also indicate that glutamine is 
able to prevent the mucosal atrophy seen after heterotopic SBT (Schroeder et a!. 
1992). Taken together, these findings indicate that glutamine could have 
important applications after SBT, worthy of investigating. 
Early detection of rejection is of vital importance in preserving barrier function, 
and may benefit long-term graft function since it could delay and or reduce 
fibrosis and chronic rejection. Several serum of urinary markers are now availabe 
which, in conjunction with histology, allow early recognition and treatment of 
rejection, and new makers are still being sought for. For example, the enzyme 
diarnino-oxidase is a potentially interesting marker for both rejection and long-
term graft function (Rose et al. 1991). This enzyme, which is involved in the 
regulation of polyamine metabolism, and probably regulation of mucosal growth, 
is produced mainly by mature enterocytes in the villus tip (Rokkas et a!. 1990"). 
It may have elevated levels in serum during acute ischemic injury of the small 
bowel mucosa (Wollin et a!. 1981) and hence may be useful in detecting acute 
rejection. Normally, after i.v. heparin administration a rapid increase of plasma 
diamino-oxidase is seen (Kobayashi et al. 1969, Luk et al. 1983). These 
postheparin plasma diamino-oxidase levels are lowered in small bowel mucosal 
damage (D'Agostino et aL 1991) and could prove to be a marker for graft 
function, which deserves further study. 
Denervation, an inevitable consequence of SBT, causes hypersecretion from the 
crypts and diarrhea in the early stages after transplantation (Watson et aL 1988, 
Meijssen et al. 1991'). It is thought that long-term impaired motility as a result 
of denervation, although not hindering passage of food, is associated with 
bacterial overgrowth. Increased chloride secretion (Meijssen 1991', Watson et al. 
1988), steatorrhea (Schraut et a!. 1988, Raju et aL1989, Thompson et al. 1992), 
and increased fecal water content (Thompson et al. 1992) are all thought to be 
long-term consequences of extrinsic denervation of the graft. 
Because these obstacles have now been traced, and are taken away or resolved, 
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and because the first successful clinical cases are being reported, there is reason 
to be optimistic about the future of clinical SBT. 
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Rats 
Male rats of the inbred Wistar-Agouti (WAG) and Brown Norway (BN) strains 
were used. The ardmals were obtained from Harlan-CPB (Austerlitz, The 
Netherlands), where they were bred under specific pathogen free conditions. The 
ardmals were 10 to 14 weeks old when they were used, and weighed between 
200-250 g. They were kept under standard laboratory conditions (12 hours light, 
12 hours dark) with water and food (Hope farms diet for rat and mouse #1410, 
Hope farms, Woerden, The Netherlands) ad libitum. The WAG strain is 
homozygous for the Rt-1• haplotype (rat major histocompatibility complex), 
whereas the BN rat is homozygous for the Rt-1" haplotype. Consequently, organ 
transplantation between these strains represents an allogeneic situation. 
The experimental protocols adhered to the rules laid down in "The Dutch 
Animal Experimentation Act" (1977) and the published "Guidelines on the 
Protection of Experimental Animals" by the Council of the E.C. (1986). Specific 
protocols were approved by the Committee on Animal Research of the Erasmus 
University, Rotterdam, The Netherlands. 
Small bowel transplantation 
One-stage total orthotopic small bowel transplantation (SBT) was performed 
according to a modification of the methods of heterotopic transplantation 
described by Monchik & Russel (1971) and orthotopic transplantation described 
by Kart et al. (1973). In brief, the method consists of end-to-side anastomosis of 
the superior mesenteric artery and portal vein of the graft to the abdominal 
aorta and caval vein of the recipient, respectively. After resection of the host's 
small bowel the graft is placed in an orthotopic position by end to end 
anastomosis of the graft proximally with the host's duodenum and distally with 
the remaining 1-2 em of terminal ileum. 
In detail, the method is as follows. 
Donor 
All procedures were performed under clean but nonsterile conditions. 
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Donors were fasted 24 h before surgery but could drink ad libitum. The donor 
was anesthetized with ether ( diethyether p.a., Merck, Darmstadt, Germany), its 
abdomen shaved, and taped onto a cork board. The abdomen was opened via a 
midline incision from pubis to xyphoid. The intestines were visualized by 
retracting the wound with two T shaped aluminum spatulas. First, the colon was 
dissected to free the small boweL This was done by ligating the right and middle 
colic arteries and veins using 4/0 silk (NC-Silk, B Braun, Melsungen AG, 
Germany) and dissection of the connective tissue between the small bowel and 
the colon and colon and pancreas. The superior mesenteric artery was 
skeletonized, thereby disrupting the intestinal lymphatics and coeliac ganglion. 
Subsequently the portal vein was visualized and the pyloric- and splenic vein 
were ligated using 4/0 silk. The donor was systemically heparinized with 200 
international units of heparin (Thromboliquine, Organon Technika BV, Boxtel, 
The Netherlands) per kg body weight given intravenously via the penile vein. 
Finally, the graft was harvested by cutting the small bowel 1 em distally from the 
ligament of Treitz and 1-2 em proximally from the caecum. The vascular pedicle 
cOnsisted of the portal vein and superior mesenteric artery including an aortic 
cuff. The graft was flushed via the superior mesenteric artery with 2 ml of chilled 
Hanks balanced salt solution (HBSS) and stored in cold HBSS while the 
recipient was prepared. 
Recipient 
The abdomen was opened via a midline incision from puhis to xyphoid and the 
wound retracted with spatulas. The intestines were wrapped in moistened gauze 
and exteriorized to the left. The abdominal aorta and inferior caval vein were 
isolated and clamped together with a curved Mosquito hemostat and longitudinal 
openings of approximately 2 mm were cut distally in the aorta and proximally in 
the caval vein. End-to-side anastomoses were performed between the superior 
mesenteric artery and portal vein of the graft and aorta and caval vein of the 
recipient, respectively, with a continuous suture with 8/0 Mirafil (B Braun, 
Melsungen AG, Germany). The total ischemic time was approximately 30 
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minutes. After ligation of its bloodvessels the total SB of the host was resected. 
The graft was anastomosed end-to-end, proximally with the host's duodenum and 
distally with the remnant 1-2 em ileum using a continuous suture with 7/0 silk 
{Ethicon, Norderstedt, Germany) (Fig. 1). The abdominal wall was closed in one 
layer with 2/0 silk (NC Silk, B Braun). At the end of the operation the animals 
received subcutaneously a single dose of 20.000 IV penicillin and 20 mg 
streptomycin (Depomycine, Mycofarm, de Bilt, The Netherlands). 
Segmental small bowel transplantation 
Jejunal transplants consisted of 10 em of proximal jejunum. Ileal grafts were 
prepared by isolating 10 em of distal ileum from the small boweL Like total 
small bowel grafts, these segments were vascularized by the superior mesenteric 
artery and portal vein. 
Postoperative monitoring 
After transplantation, rats received standard rat chow and water ad libitum. The 
animals were examined for signs of graft-versus-host disease and were weighed 
three times a week. Weight gain or loss was considered the most important 
indicator for graft function. All rats that died within 4 days were considered to 
be technical failures. After death, autopsy was performed to confirm or exclude 
rejection, using the criteria published by Schraut & Lee (1986). Briefly, acute 
graft rejection was indicated by signs of peritonitis, a thin-walled distended graft 
and unimpaired intestinal anastomoses. Usually, the mesenteric lymph nodes of 
the graft were enlarged. 
Histology 
For histopathologic analysis tissues were flxed in 3.6% buffered formalin. After 
dehydrating and embedding, 3-4 )l.m sections were cut and stained with 
hematoxilin-floxine saffron. 
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Fig.L Model of orthotopic small bowel transplantation. The superior mesenteric 
artery (SMA) and portal vein (PV) of the graft are anastomosed end-to-side to the 
recipient aorta (A) and caval vein (CV), respectively. 
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GVHD 
The occurrence of GVHD after SBT was first described by Monchik & Russel 
(1971). Clinically it is chatacterized by redness of eatS, snout and paws, followed 
by scaling, hairless and diarrhea. 
The severity of GVHD was estimated by clinical grading as follows. 
Grade 1: light redness of eatS, snout and paws. 
Grade 2: Moderate redness of eatS, snout and paws; light hair loss and diarrhea. 
Grade 3: Severe redness of eatS, snout and paws; alopecia, generalized 
dermatitis and profuse diarrhea. 
Cyclosporine A 
Commercially available cyclosporine (Sandimmun, Sandoz, Basel, Switzerland) 
was obtained and dissolved in olive oil to a concentration of 50 mgjml before 
intramuscular administration. 
Anti-lymphocyte serum 
Rabbit-anti-rat anti lymphocyte serum was produced by subcutaneous injection of 
108 rat thymocytes suspended in complete Freund's adjuvant. Subcutaneous 
booster injections with lOS thymocytes were given after 14, and 28 days. Blood 
was collected one week after the last immunization, the serum was prepated and 
decomplemented at 56 oc for 1 hour. The serum was shown to be effective in a 
rat heatt allotransplantation model in which it prolonged graft survival from 
8.5±0.5 days to 27±1.1 (MST±SD) days when it was given to the recipient 
subcutaneously on days 0,1, and 2 after transplantation in a volume of 4 ml/kg. 
Irradiation 
Whole-body irradiation was performed with a Gatmnacell-40 137Caesium 
irradiation unit (Atomic Energy of Canada, Ltd), 1·4 hr before transplantation. 
Other materials and methods are described in the chapters they ate relevant to. 
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SUMMARY 
Rejection and graft-versus-host disease (GVHD) are prominent features in small 
bowel allotransplantation in rats. Cyclosporine A (CsA) treatment of the 
recipient and irradiation of the donor were employed to circumvent these 
phenomena in the WAG to BN rat model. Irradiation of the donor with 5 or 10 
Gy did prevent GVHD but resulted in a more vigorous rejection of small bowel 
allografts in untreated recipients (mean survival times (MST±SE) of 11.5±0.4 
(n=8) and 7.5±0.9 (n=ll) days respectively, versus 16.6±2.6 days (n=17), (p 
<0.01). CsA treatment of the recipient (25 mg/kg on days 0,1,2,4 and 6 after 
transplantation) led to a MST of 38.3±8.5 days (n=10); 20% of the animals 
developed GVHD. Combined with 5 Gy donor pretreatment, a similar survival 
was obtained without occurrence of GVHD. However, CsA treatment combined 
with 10 Gy led to a significant shortening of graft survival (MST 23.1±6.8 days, 
(n=9)). These results suggest that, although irradiation is very effective in 
preventing GVHD, high dosages may accelerate rejection by either making the 
graft more vulnerable to rejection or by completely removing the 
immunosuppressive effect of GVHD. 
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INTRODUCTION 
Various experimental studies on the rejection of small bowel allografts have 
shown that under certain immunological conditions, immunocompetent cells in 
these grafts can cause graft-versus-host disease (GVHD) (Monchik & Russell 
1971, Deitz et a!. 1981, Schraut et a!. 1986, Schraut, 1988). While the occurrence 
of the GVH-reaction in well-defined inbred systems has been conclusively 
documented, its significance in outbred systems is uncertain. In a previous study 
we successfully ameliorated GVHD in the WAG to BN rat model using whole-
body irradiation of the donor with 10 Gray (Gy) (Saat et al. 1989). The 
effectiveness of donor irradiation has been shown previously in a parent to F1-
hybrid rat model in which the donors were irradiated with 7, 9.5 and 10 Gy 
before small bowel transplantation (SBT) (Monchik & Russell 1971, Lee et a!. 
1985, Deitz et a!. 1986). In the present study we investigated the effects of 
combined cyclosporine A (CsA) therapy and donor irradiation because we had 
evidence that irradiation of the donor leads to an accelerated rejection of the 
graft (Saat et al. 1989). We wondered whether CsA therapy could reverse this 
effect. Earlier we found that CsA, used alone, was not effective in consistently 
producing long-term survivors in the WAG to BN donor-host combination (Saat 
et a!. 1990). In this study we show that the effect of CsA on GVHD is less 
pronounced than its effect on rejection, as shown earlier by Kirkman (1984). In 
large animal models CsA proved to be less successful than in certain rat strain 
combinations (Craddock et al. 1983, Diliz-Perez et a!. 1984, Harmel et al. 1986, 
Lee et a!. 1986, Hatcher et al. 1987, Kirkman et a!. 1987, Schraut et a!. 1987, 
Shimazu et a!. 1988). Two recent studies in pigs, using ex-vivo irradiation of the 
transplant with 0.5 Gy, a very low dose, combined with CsA therapy of the 
recipient showed no effect on host survival time compared to CsA monotherapy 
(Pritchard & Kirkman 1985, Grant et a!. 1988). Because the immunological 
problems of large animal models resemble the problems in our WAG to BN rat 
model, this model is highly suitable for investigating the effect of irradiation 
combined with CsA therapy. 
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MATERIAL AND METHODS 
Animals: a fully allogeneic donor-host model was employed by using inbred 
WAG (RTlu) rats as donors and inbred Brown Norway (RTl") rats as recipients 
as described in chapter 2. 
Operative procedures: were performed as described in chapter 2. Briefly, the 
small bowel was double-tied and cut 1 em distally to the ligament of Treitz and 
1-2 em proximally to the caecum. The graft was harvested along with the 
attached vascular pedicles, consisting of the ponal vein and the superior 
mesenteric artery. including an aortic cuff. End to side anastomoses were 
performed between the graft superior mesenteric artery and the aona, and the 
graft ponal vein and inferior caval vein, respectively. The host's small bowel was 
resected and the donor small bowel was anastomosed end to end, proximally 
with the duodenum, distally with the remnant of the ileum at 1-2 em from the 
caecum. 
Postoperative care: as described in chapter 2. 
Immunosuppression: CsA was administered as described in chapter 2 .. 
Irradiation: was performed as described in chapter 2. 
GVHD: the severity of GVHD was estimated by clinical grading as described in 
chapter 2; Grade 1: light redness of ears, snout and paws. Grade 2: moderate 
redness of ears, snout and paws; light hair loss and diarrhea. Grade 3: severe 
redness of ears, snout and paws; alopecia, generalized dermatitis and profuse 
diarrhea. 
Statistics: the survival data were statistically analized using the Wilcoxon rank-
sum test for group comparison. 
EXPERIMENTAL GROUPS 
Six groups were distinguished (see Table I); 
Group 1: Controls, WAG to BN, no immunosuppressive therapy, n=17. 
Group 2: Irradiation of the donor with 5 Gy, n=8. 
Group 3: Irradiation of the donor with 10 Gy, n=11. The results for this group 
have been published before (Saat et al. 1989). 
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Group 4: Administration of 25 mg/kg of CsA on days 0,1,2,4 and 6 after 
transplantation, n; 10. 
Group 5: Irradiation of the donor with 5 Gy in combination with 25 mg/kg of 
CsA given on days 0,1,2,4 and 6 after transplantation to the recipient, n; 9. 
Group 6: Irradiation of the donor with 10 Gy in combination with 25 mg/kg of 
CsA given on days 0,1,2,4 and 6 to the recipient, n;9. 
RESULTS 
Table 2 shows that untreated control rats died after a mean survival time ± 
standard error of the mean (MST±SE) of 16.6±2.6 days. Six of 17 rats showed 
grade 1-2 symptoms of GVHD for 3-4 days. In groups 2 and 3, whole-body 
irradiation of the donor with 5 and 10 Gy respectively resulted in a complete 
abscense of GVHD. Surprisingly, the survival times in both groups were 
significantly shorter than those in the control group (11.5±0.4 and 7.5±0.9 days 
resp. vs 16.6±2.6 days, P<O.Ol). The accelerated graft rejection was more 
vigorous in group 3 than in group 2 (P < 0.02). Rats in group 4 that received 25 
Table 1. Schedule of graft pretreatment and immunosuppression. 
group n 
1 17 
2 8 
3 11 
4 10 
5 9 
6 9 
pretreatment1 
5 Gy, in vivo 
10 Gy, in vivo 
5 Gy, in vivo 
10 Gy, in vivo 
immunosuppression2 
CsA 
CsA 
CsA 
1: Whole body irradiation was performed 1-4 hr before transplantation using 
a Caesium-137 gamma-source. 
2: Cyclosporine A was given intramuscularly in doses of 25 mg/kg on days 
0,1,2,4 and 6 after transplantation. 
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mgjkg CsA, survived with a mean of 383±85 days; 2 of 10 rats developed 
clinical symptoms of GVHD. Pretreatment with 5 Gy in combination with CsA 
therapy (group 5), produced no significant difference in survival time when 
compared with group 4 (472:!:6.8 vs 38.3±8.5 days). However, none of the rats 
in group 5 showed signs of GVHD or peritonitis. One rat died on day 58 as a 
result of a late technical complication: stenosis of the proximal intestinal 
anastomosis. In group 6, irradiation with 10 Gy and CsA therapy resulted in a 
MST that was significantly shorter than that found in group 4 (23.1±6.8 vs 
38.3:!:8.5 days, p <0.01). At autopsy, 4 of the recipients that died in the first 
week showed symptoms of peritonitis as a result of a vnlnerahle, glassy 
transplant. No GVHD was observed in this group. Most rats in groups 4, 5 and 6 
that survived more than 3-5 weeks increased in weight. In comparison with the 
weight gain observed earlier in a syngeneic (WAG-WAG) study, in which the 
Table 2, Effect of donor pretreatment and immunosuppression on the survival of 
orthotopic small bowel transplantation in rats. 
group survival in days 
1 6,6,6, 7 ,8,8, 133 ,14, 14, 15,15,19'\21 a, 
24,27",31",47". 
2 10,11,11, 11,11, 12,12,14 
3 5,5,6,6,6,6,6,7,10,12,13 
4 8, 11, 13, 13,21,55,59b,65,66', 72 
5 11, 17,31,34, 49,55,57,58, 72 
6 5,6,7, 7, 7,35,39,48,54 
a: grade 1-2 severity of graft-versus host disease 
b: grade 3 severity of graft-versus host disease 
mean:!: SE 
16.6 ;: 2.6 
11.5 :!: 0.4 
7.5 ;: 0.9 
38.3 ;: 8.5 
42.7 ;: 6.8 
23.1 :!: 6.8 
group 2 and 3 significantly worse compared with group 1, p < 0.01 
group 2 significantly better compared with group 3, p < 0.02 
group 5 not significantly different from group 4 
group 6 significantly worse compared with group 4, p < 0.01 
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donor was irradiated with 10 Gy, however, the weight gain was minimal (Saat et 
al. 1989). 
DISCUSSION 
This study clearly shows that irradiation of the donor very effectively prevents 
the occurrence of clinical GVHD. In addition, when GVHD is ameliorated or 
absent in a fully allogeneic rat model, the acute rejection in untreated recipients 
is accelerated. This vigorous rejection can be explained by the assumption that 
irradiation with 10 Gy releases more immunocompetent cells in the peripheral 
circulation of the recipient than irradiation with 5 Gy. Although we cannot 
exclude this effect, it is our opinion that the vigorous rejection can only be 
controlled by CsA therapy when GVHD is not completely abrogated. The 
mechanisms that are probably responsible for these results have been described 
in experiments concerning GVHD in bone marrow transplantation (Seddik et al. 
1984, Stet, 1987). These studies showed that a GVH-reaction can induce a state 
of permanent suppression of cell-mediated and of humoral immune responses. 
This functional abnormality of T cells or B cells, or both, is probably related to a 
maturation defect (Seddik et al. 1984). Therefore the absence of GVHD, with its 
inherent immunosuppressive effect, is the most plausible explanation for the 
vigorous rejection that occurred in irradiated donors. From studies in a 
semiallogeneic parent to Fl-hybrid rat model it is known that irradiation with 5 
Gy, in contrast to 10 Gy, failed to prevent the onset of GVHD (Lee et al. 1985). 
Extrapolating these data to our results, we presume that the immunosuppressive 
effect of subclinical GVHD was responsible for the benificial effect on the 
survival time when donors were irradiated with 5 Gy compared with 10 Gy. 
Moreover, the abscence of clinical GVHD may be of clinical importance. 
Until now it has been uncertain to what degree, if any, GVHD will complicate 
human SBT. Under the assumption that GVHD will develop after SBT, 
strategies have to be developed to circumvent this complication. In theory, drug 
treatment or irradiation of the transplant before surgery would be the ideal 
method to inactivate donor lymphocytes. Practically, irradiation is the easiest 
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procedure and can be performed ex vivo without losing its effect (Lee et a!. 
1985). 
Obviously, the major problem in SET remains the vigorous rejection process and 
its suppression. CsA will be the most important drug in any standard 
intmunosuppressive regimen. This study gives indirect evidence that irradiation 
of the donor in combination with CsA therapy is useful only when some 
intmunocompetent cells in the graft, capable of producing a subclinical GVHD 
whose immunosuppressive effect is beneficial to the survival of the allografts are 
left. It is necessary to quantify further the donor irradiation dose that will resnlt 
in the optimal interaction between the occurrence of GVHD and rejection of the 
graft. 
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SUMMARY 
After fully-allogeneic small bowel transplantation (SBT) both graft-versus-host 
disease (GVHD) and rejection may occur. Donor-pretreatment may prevent 
GVHD, but this sometimes leads to accelerated graft rejection. To study a 
possible balance between GVHD and rejection, fully-allogeneic total orthotopic 
SBT was performed in rats using the WAG to BN donor-host combination. 
Untreated control grafts were rejected in 16.6±2.7 days (mean±SE), and 35% of 
the animals had mild, transient GVHD. Pretreatment of the donor with anti-
lymphocyte serum (ALS) on days -2 and -1 before grafting, either intravenously 
or intraperitoneally, completely eliminated the occurrence of clinical GVHD, but 
led to significantly shortened survival times (12.3±0.8 and 10.3±0.9 days, 
respectively). Donor pretreatment with 50 mgjkg cyclosporine A (CsA) on days -
2, and -1 prolonged graft survival significantly to 22.1 days, but had no significant 
effect on the incidence of GVHD. Administration of 25 mgjkg CsA on days 
0,1,2,4, and 6 after grafting prolonged survival to 38.3 days with no evidence of 
GVHD. Pretreatment of the donor with ALS combined with the same postope-
rative short term CsA regimen increased survival to more than 50 days, again 
with no evidence of GVHD. When CsA was used as both donor pretreatment 
and postoperative therapy there was no survival advantage compared to the use 
of postoperative CsA alone. These results show that an in vivo balance between 
GVHD and rejection exists, and that abrogation of GVHD leads to accelerated 
rejection. Immunosuppression of the recipient may overrule this accelerated 
rejection, while preserving the beneficial effect of donor-pretreatment: eliminati-
on of clinical GVHD. 
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INTRODUCTION 
As was first shown in the parent to F1 hybrid rat mode~ transplantation of the 
small bowel may produce a lethal graft-versus-host-disease (GVHD) (Monchik & 
Russell 1971). This GVHD shows histological similarities to that induced by 
bone-marrow transplantation (Miiller-Hermelink & Deitz 1986), and is caused by 
T-lymphocytes originating from the transplanted gut and its mesenteric lymph 
nodes (Kirkman et a!. 1984, Wallander et a!. 1989). 
In fully allogeneic models of small bowel transplantation (SBT), in which both 
GVHD and host-versus-graft (rejection) reactions may occur, rejection predonti-
nates. However, 30%-50% of the animals transplanted with a total small bowel 
without inununosuppression show clinically overt GVHD (Saat et a!. 1989). This 
GVHD is characterized by a redness of ears, snout, and paws, and, in more 
severe cases, also includes dermatitis, alopecia, and a hunched posture of the 
animals. It is distinguished from GVHD in the one-way model by its nonlethal, 
short-lived, transient nature. Immunomodulation of the recipient and/or the 
donor can dramatically alter this picture. From studies in one-way models it is 
known that the immunosuppressive agent cyclosporine A (CsA) has greater 
impact on rejection than on GVHD (Kirkman et aL 1984). When CsA is given at 
a critical dose following fully-allogeneic transplantation, GVHD can be more 
severe than in untreated animals, while rejection is delayed (de Bruin et a!. 
1990). 
In both the one-way and the fully-allogeneic models of SBT GVHD can be 
elintinated by reducing the mass of lymphoid tissue in the graft (Lee & Schraut 
1985, Deitz et aL 1986). Surprisingly, elintinating GVHD sometimes leads to 
accelerated graft rejection in fully-allogeneic models (Saat et aL 1991). This 
finding suggests that there is an immunological balance between rejection and 
GVHD (Cohen et aL 1976), and that GVHD in some way prevents the develop-
ment of rejection by attacking the host immune system. 
Previous data obtained in our laboratory substantiate this hypothesis. We have 
shown that irradiation of the donor with 5 or 10 Gray prevents the occurrence of 
clinical GVHD and leads to accelerated graft rejection. This study also gave 
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indirect evidence that subclinical GVHD may benefit graft survival (Saat et a!. 
1991). However, most studies on GVHD following SBT have used one-way 
models, and further study of the fully-allogeneic model is required to substaotia-
te this hypothesis (Watson & Lear 1989). 
The aim of the present study was to determine whether donor-pretreatment with 
anti-lymphocyte serum (ALS) or GsA could also suppress GVHD, and what 
effect this pretreatment might have on graft survival following total orthotopic 
fully-allogeneic SBT. 
MATERIAL AND ME1HODS 
Animals: rats of the inbred WAG (Rtlu) and BN (Rt1°) strains were used as 
donors and recipients, respectively, as described in chapter 2. 
Small bowel transplantation: was performed as described in chapter 2. In brief, 
the total small bowel was harvested from the ligament of Treitz to the terminal 
ileum, along with a vascular pedicle consisting of the superior mesenteric artery 
and portal vein. In the recipient the infra-renal aorta and caval vein were 
clamped and end-to-side anastomoses were performed between the recipient 
aorta and caval vein and the donor superior mesenteric artery and portal vein, 
respectively. The recipient small bowel was resected, and the graft was placed in 
an orthotopic position by end-to-end anastomoses proximally with the host's 
duodenum and distally with the remaining 1-2 em of terminal ileum. 
Post-operative monitoring: after surgery, animals received standard laboratory rat 
chow and water ad libitum. The animals were weighed 3 times a week and were 
inspected daily for signs of clinical GVHD. Three grades of GVHD were distin-
guished as described in chapter 2. Grade 1: light redness of ears, snout and 
paws. Grade 2: moderate redness of ears, snout ans paws, light hair-loss and 
diarrhea. Grade 3: severe redness of ears, snout and paws, alopecia, generalized 
dermatitis and diarrhea. Rats that died within 4 days from transplantation were 
considered technical failures. After death, autopsy was performed to confirm or 
exclude rejection. 
Cyclosporine A: commercially available CsA was obtained and dissolved in olive 
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oil to a concentration of 50 mg/ml before intramuscular administration_ 
Statistics: The Wilcoxon rank-sum test and the chi-square test were used for 
statistical analysis of the data. 
Anti-lymphocyte sernm: was prepared as described in chapter 2. 
EXPERIMENTAL GROUPS 
The following groups were studied using the WAG to BN fully-allogeneic orthotopic 
total SBT model; 
Group 1: Control group, no immunosuppressive therapy, (n = 17). 
Group 2: Donor pretreatment on days -2, and -1 prior to transplantation with 4 
ml/kg ALS intravenously, (n=7). 
Group 3: Donor pretreatment on days -2, and -1 with 4 ml/kg ALS intraperiton-
eally (n = 10). 
Group 4: Donor pretreatment on days -2, and -1 with 50 mg/kg CsA, given 
intramuscularly (n=8). 
Group 5: Recipient treatment with 25 mgjkg CsA intramuscularly on days 0, 1, 
2, 4, and 6 after transplantation (n= 10) 
Group 6: Donor pretreatment on days -2, and -1 with 4 ml/kg ALS intravenous-
ly, recipient received 25 mgjkg CsA on days 0, 1, 2, 4, and 6 after transplan-
tation (n=7). 
Group 7: Donor pretreatment on days -2, and -1 with 4 mljkg ALS intraperiton-
eally, recipient treatment with 25 mgjkg CsA on days 0, 1, 2, 4, and 6 after 
transplantation (n=7). 
Group 8: Donor pretreatment on days -2, and -1 with 50 mgjkg CsA intramus-
cularly, recipient received 25 mgjkg CsA on days 0, 1, 2, 4, and 6 after transpla-
ntation (n=9). 
RESULTS 
Untreated controls (group 1) died from rejection after a mean survival time 
(MST) ± standard error of the mean (SE) of 16.6±2.7 days. Of these animals, 
35% showed grade 1-2 symptoms of GVHD for 3-4 days between 9 and 12 days 
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Table 1: The effect of donor-pretreatment and recipient immunosuppression on small 
bowel allograft survival in tbe fully-allogeneic WAG to BN donor-host combination_ 
group donor recipient survival in days MST±SE %GVHD 
pretreatment1 treatment2 
1 6,6,6,7,8,9,133,14, 16.6±2.7 35 
14,15,15,19',21 ',24, 
27',31',47' 
2 ALS iv 10, 11, 11,11,13, 14,16 12.3±0.8 0 
3 ALSip 5,8,8,9, 10, 12, 12,13 10.3±0.9 0 
13,13 
4 CsA im 13,13'\14b,20a,24,25, 22.1±3.4 62 
27',41b 
5 CsAim 8,11,13,13,21,55,59b, 38.3±8.5 20 
65,66',72 
6 ALS iv CsAim 7,11,13,62,63,69,137 51.7± 17.6 0 
7 ALSip CsAim 7, 12,16,62,84,99, 104 54.8± 16.1 0 
8 CsA im CsAim 9, 14, 17,22,24b,25b, 38.4±10.2 33 
70b,79,86 
1: Anti-lymphocyte serum (ALS) was given intravenously (iv) (groups 2 and 6), or 
intraperitoneal!y (ip) (groups 3 and 7) on days -2 and -1 prior to transplantation in a 
volume of 4 mljkg. Cyclosporine A (CsA) pretreatment was given intramuscularly 
(im) on days -2, and -1 prior to transplantation at a dose of 50 mg/kg. 
2: Recipients were given 25 mg/kg cyclosporine A (CsA) intramuscularly (im) on days 
0,1,2,4, and 6 after transplantation. 
3: percentage of animals showing clinical signs of GVHD 
a: animals showing grade 1-2 GVHD. 
b: animals showing grade 3 GVHD. 
Survival group 1 vs groups 2, 4, 5, 6, 7, 8: p < 0.01. Group 1 vs group 3: p < 0.05, 
Wilcoxon rank-sum test. 
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after transplantation (Table 1). Donor pretreatment with ALS, either intrave-
nously or intraperitoneally (groups 2 and 3), successfully prevented the occurren-
ce of GVHD; none of the animals displayed clinical signs of GVHD. Graft 
survival in these groups was significantly shortened as compared to untreated 
controls (12.3±0.8 and 10.3±0.9 days respectively, p<0.05). 
Donor pretreatment with CsA (group 4) significantly prolonged graft survival 
(MST±SE 22.1±3.4 days, p<O.Ol), while 62% of the animals developed clinical 
GVHD. Of these, 60% had grade 1-2, and 40% had grade 3 GVHD. CsA given 
to the recipient at a dose of 25 mg/kg on days 0, 1, 2, 4, and 6 after grafting 
(group 5) led to a significant prolongation of graft survival time (38.3 ± 8.5 days, 
p<0.01). Twenty percent of the animals developed GVHD. 
Pretreatment of the donor with ALS, either intravenously or intraperitoneally, 
combined with CsA treatment of the recipient (groups 6 and 7, respectively), led 
to survival times that were not significantly different from CsA treatment of the 
recipient alone (51.7 ± 17.6 and 54.8± 16.1 days, respectively). None of these 
animals showed signs of GVHD. 
Donor pretreatment with CsA combined with recipient CsA treatment (group 8) 
gave the same MST as CsA treatment of the recipient alone (38.4± 10.2 days). 
All animals showing GVHD (33%) had grade 1-2 severity. 
DISCUSSION 
Monchik & Russell (1971) first used parent and F1 hybrid models in SET. They 
showed that both unidirectional rejection and GVHD can be induced by small 
bowel grafts, and that pretreatment of the donor with 7 Gy total body irradiation 
prior to transplantation completely eliminates GVHD. These findings have been 
confirmed by other studies (Lee & Schraut 1985, Deitz et al. 1986). Observations 
in these unidirectional GVHD or rejection models are of uncertain relevance to 
the clinical situation, in which a two-way reaction between rejection and GVHD 
can occur (Kirkman, 1984 ). In fully-allogeneic SET, rejection rather than GVHD 
seems to predontinate, but little documentation is available on the interaction 
between rejection and GVHD in these models. In some fully-allogeneic rat 
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models, the animals die from rejection while GVHD is not clinically present 
(Monchik & Russell 1971, Lee & Schraut 1986, Frantz et a!. 1988). Cohen et a!. 
(1976) investigated the effect of graft-irradiation with 0.5 and 1,5 Gy prior to 
transplantation in a canine small bowel allograft model. They found that 
pretreatment with 1.5 Gy leads to rejection of the small bowel allografts in 9.2 
days, pretreatment with 0.5 Gy, however, prolongs graft survival to a mean of 28 
days. This interesting finding has led to the hypothesis that there is a balance 
between rejection and GVHD, and that the existence of subclinical GVHD after 
0.5 Gy irradiation results in prolonged graft survival. 
Since the early 1960s it has been known that GVHD depresses the host's 
immunological reactivity (Howard & Woodruff 1961). This is best shown by 
clinical results obtained with T-ceJI depleted bone-marrow transplantation. On 
the one hand, T-cell depletion significantly reduces acute GVHD, on the other 
hand it substantially increases graft rejection (Storb, 1989). GVHD is also known 
to be immunosuppressive after experimental spleen-cell-, and small bowel 
transplantation (Grant et a!. 1989). 
Histopathologically, GVHD is characterized by a loss of the normal architecture 
of the spleen, lymph nodes and thymus (Deitz et a!. 1981, Schraut et a!. 1986, 
Grant et a!. 1989). This leads to a profound immunosuppression with impaired 
humoral and cell-mediated immune responses (Grant et al. 1989). This im-
munosuppression probably accounts for the observed in vivo balance between 
rejection and GVHD. 
Diflo et a!. (1989) observed the occurrence of a short, sublethal GVHD ap-
proximately 4 to 6 weeks after fully-allogeneic transplantation in immunosup-
pressed animals. Donor-pretreatment with ALS completely elintinated GVHD 
but had no effect on graft survival in these immunosuppressed hosts. Gundlach 
et a!. (1989) found that mesenteric lymphadenectomy, a method that bas been 
shown to eliminate GVHD (Pirenne et a!. 1990), does not influence the course 
of acute graft rejection in non-immunosuppressed recipients. However CsA was 
not effective in preventing chronic rejection following mesenteric lymphadenec-
tomy whereas the same dosage of CsA fully prevented rejection of normal smaJI 
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bowel grafts. They suggested that the absence of an immunosuppressive effect 
caused by a GVH reaction had led to chronic rejection in this model. 
In the present study, we showed that pretreatment of the donor with ALS 
eliminated clinical GVHD and led to significantly accelerated rejection. Intrape-
ritoneal and intravenous adntinistration of ALS were equally effective in pre-
venting GVHD. As Shaffer et a!. (1988) have shown that subcutaneous treatment 
is as effective as intraperitoneal treatment, the route of administration seems to 
be unimportant. 
When our recipients of a graft pretreated with ALS received immunosuppressive 
treatment with CsA, no adverse effect on graft survival was seen anymore, 
whereas clinical GVHD remained suppressed. This important finding is in 
accordance with earlier findings from our laboratory that show that irradiation of 
the donor with 5 or 10 Gy eliminated clinical GVHD and led to significantly 
accelerated graft rejection (Saat et al. 1991). When recipients of a graft which 
was irradiated with 5 or 10 Gy received immunosuppressive treatment witb CsA, 
graft survival was prolonged in both groups, whereas clinical GVHD did not 
occur. 
After CsA treatment of the donor, we found prolonged graft survival but no 
significant difference in the percentage of animals developing GVHD. However, 
2 out of 5 animals that developed GVHD had grade 3 severity. It is known that 
CsA is more effective against rejection than it is against GVHD (Kirkman et a!. 
1984). Hence, the prolonged survival we observed could have been due to the 
immunosuppressive effect of GVHD and the CsA transferred with the graft. 
Treatment of both donor and recipient with CsA had no beneficial effect on 
GVHD or rejection compared to recipient treatment alone. 
Thus, ALS pretreatment of the donor, combined with CsA treatment of the reci-
pient, results in significantly prolonged graft survival, while clinical GVHD is 
suppressed. Whether manipulation of this balance will be of use in future clinical 
SBT remains to be established. 
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CHAPTERS 
THE EFFECT OF CYCLOSPORINE A IN SMALL BOWEL 
TRANSPLANTATION IN RATS IS DEPENDENT 
ON THE RAT STRAIN COMBINATION USED 
This chapter is a modified version of the article: 
The effect of cyclosporine A in small bowel transplantation is 
dependent on the rat strain combination used. 
R.W.F. de Bruin, R.E. Saat, E. Heineman, J. Jeekel, and R.L. Marquet. 
Transplant. Proc. 1990; 22: 2472-2473. 
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SUMMARY 
Cyclosporine A (CsA) is very effective in preventing the rejection of small bowel 
allografts in some reported rat models. We have tested the effect of different 
CsA dosages on the survival of total orthotopic small bowel allografts in the 
fully-allogeneic WAG to BN and BN to WAG donor-recipient combinations. 
In the WAG to BN combination, control animals had a mean survival time 
(MST) of 16.6±2.7 (SE) days. CsA, 15 mg/kg given on days 0,1,2,4, and 6 after 
transplantation, did not significantly prolong graft survival times. Interestingly, 
50% of the rats developed graft-versus-host disease (GVHD), and 5 rats even 
exhibited a grade 3 GVH reaction of which they died. CsA 25 mg/kg on days 
0,1,2,4, and 6 after grafting led to a MST which was significantly longer than in 
the control group, although no permanent survival was seen (MST: 383 ± 8.5, 
p<0.01, Wilcoxon rank-sum test). When CsA given as in the previous group was 
followed by a maintenance therapy of 15 mg/kg 3 times a week until day 100, 3 
of 9 rats survived for more than 100 days. However, after cessation of CsA 
therapy the animals died from chronic graft rejection. 
In the BN to WAG combination untreated animals showed a MST of 12.2± 1.8 
days. Fifty percent of the animals showed a mild GVHD occurring between days 
5 and 9 posttransplant. The administration of 5 mg/kg CsA on days 0,1,2,4, and 
6 after transplantation already evoked a significant prolongation of graft survival. 
One animal survived for more than 100 days, 1 animal died with a functioning 
graft 72 days after transplantation, and 3 of 5 animals died after 41.0± 11.5 days. 
After 15 mg/kg, 5 of 8 animals survived permanently (>200 days). This CsA 
dose also effectively suppressed GVHD. Treatment with 25 mg/kg CsA gave the 
same MST as in the control group. In this group, no clear-cut rejection could be 
demonstrated and 1 animal died from functional ileus of the transplant. From 
this smdy we conclude that the effectiveness of CsA treatment on the survival of 
small bowel allografts is dependent upon the donor-recipient combination used, 
and that "hard" models exist which are relevant in preclinical studies on small 
bowel transplantation. 
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INTRODUCfiON 
Succesful clinical small bowel transplantation (SBT) is hampered by the powerful 
rejection of the graft. In contrast to the clinical situation, in some rat models 
long term graft survival is easy to achieve using cyclosporine A (CsA) as a single 
immunosuppressive agent. In a heterotopic model 15 mg/kg of CsA per day for 
7 days resulted in indefinite graft survival in the (LBN)F1-hybrid to Lew 
combination, and markedly prolonged survival in the Lew to (LBN)Fl 
combination (Kirkman et al. 1985, Pritchard et al. 1985). Others have reported 
similar results after prolonged administration of CsA, in doses varying from 15 to 
20 mg/kg/ day (Harmel et al. 1986, Lee et al. 1986, Hatcher et al. 1987, Schraut 
et al. 1987). CsA has proved to be much less effective in large animal models. 
Although statistically significant graft survival is found, long-term survival is ouly 
ocasionally achieved (Craddock et al. 1983, Diliz-Perez et al. 1984, Kirkman, 
1984). 
Previous studies in our laboratory have shown that the BN rat is a high 
responder to the WAG rat (Niessen et al. 1982). To reduce the costs and 
difficulties of a large animal model, we sought to determine whether a rat model 
could be found which exhibited the immunological problems of the large animal 
model, and thus would not consistently show prolonged small bowel allograft 
survival after CsA treatment. The present study was undertaken to investigate 
the effect of different CsA treatment schedules on the survival of small bowel 
allografts in the "hard" WAG to BN as well as in the "moderate" BN to WAG 
donor-host combination. 
MATERIALS AND METHODS 
Animals: rats of the inbred BN (Rtl ') and WAG (Rtl ") strains were used as 
described in chapter 2. 
Intestinal transplantation: transplantation was performed as described in chapter 
2. Briefly, the total small bowel, from the ligament of Treitz to the terminal 
ileum was harvested. The recipients infra~renal aorta and caval vein were 
clamped and end-to-side anastomoses were performed between the recipient 
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aorta and caval vein and the donor superior mesenteric artery and portal vein, 
respectively. The recipient small bowel was resected and the graft was 
anastomosed proximally with the host's duodenum and distally with the 
remaining terminal ileum. 
After transplantation, rats were weighed 3 times a week and were examined for 
signs of graft versus host disease (GVHD). After death, necropsy was performed. 
GVHD: The severity of GVHD was estimated by clinical grading. as described in 
chapter 2. Grade I: light redness of ears, snont and paws. Grade 2: moderate 
redness of ears, snout and paws, light hairloss and diarrhea. Grade 3: severe 
redness of ears, snout and paws, alopecia, dermatitis and profuse diarrhea. 
Statistics: The survival data were statistically analysed using the Wilcoxon rank-
sum test. 
EXPERIMENTAL GROUPS 
WAG to BN donor-host combination; 
Group 1: Controls, no treatment (n= 17). 
Group 2: 15 mg/kg CsA given intramuscularly (im) on days 0,1,2,4 and 6 after 
grafting (n=l4). 
Group 3: 25 mgjkg CsA im on days 0,1,2,4 and 6 after grafting (n=lO). 
Group 4: 25 mgjkg CsA im on days 0,1,2,4 and 6, followed by 15 mgjkg given 3 
times a week as maintenance therapy until day 100 (n=9). 
BN to WAG donor-host combination; 
Group 5: Controls, no treatment (n=10). 
Group 6: 5 mgjkg CsA im on days 0,1,2,4 and 6 (n=5). 
Group 7: 15 mg/kg CsA im on days 0,1,2,4 and 6 (n=8). 
Group 8: 25 mgjkg CsA im on days 0,1,2,4 and 6 (n=6). 
RESULTS 
Table 1 shows that in the WAG to BN combination control animals had a mean 
survival time (MST) of 16.6±2.7 (SE) days. Six rats (35%) developed a grade 1-2 
manifestation of GVHD. Symptoms became evident on days 9 to 10 posttransplant, 
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Table 1. Effect of cyclosporine A on the survival of small bowel allografts in the 
WAG to BN donor-host combination. 
treatment survival in days MST:tSEa 
1. 6,6,6, 7,8,8, 13b, 14, 14, 15, 15, 19b,21 b,24,27b,31 b,4 7b 16.6 :t 2. 7 
2. 15 mg/kg CsA 1 
3. 25 mg/kg CsA1 
4. 25 mg/kg CsA 12 
5,6,7,8,17,19°,19' ;zob ;zo' ;21 ';zs' ;26,41,57' 
8, 11, 13•, 13•,21,55,59',65,66b, 72 
8,12.,19,26',27b,51b,179,212,300 
a: mean survival time ± standard error of the mean, 
b: animals exhibited grade 1-2 GVHD 
c: animals exhibited grade 3 GVHD, d: functional ileus of the graft. 
20.8:t3.8 
383:t8.5 
92.6:t36.2 
1: CsA was given on days 0,1,2,4 and 6. 2: CsA 15 mg/kg 3 times a week until 
day 100. 
and disappeared within 3-4 days (Table 3). A short course of 15 mgfkg CsA 
(group 2) did not significantly prolong graft survival. Interestingly, 50% of the 
rats developed GVHD, of which 30 % developed grade 1-2 symptoms, and 70% 
GVH grade 3 reaction of which they died. The onset of GVHD in this group 
was approximately 9 days later than in group 1 (Table 3). In group 3, the 
animals were treated with a higher dose of CsA; 25 mg/kg. The MST was 
significantly longer than in the control group, although no permanent survival 
was seen (MST: 38.3:t8.5, p<0.01, Wilcoxon rank-sum test). Twenty percent of 
the animals developed a transient GVHD. At necropsy, 2 animals in this group 
revealed functional ileus of the graft as cause of death. In group 4, where this 
high-dose CsA given during the first week posttransplant was followed by a 
maintenance therapy, 3 of 9 rats survived for more than 100 days. However, after 
cessation of CsA therapy the animals died from chronic graft rejection. No 
beneficial effect on the suppression of GVHD was seen either; 33% of the 
animals developed clinical GVHD. 
In the BN to WAG combination untreated animals showed a MST of 12.2:t 1.8 
days (Table 2). Fifty percent of the animals developed a mild GVHD that 
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Table 2. Effect of cydosporine A on the survival of small bowel allografts in the 
BN to WAG donor-host combination. 
treatment survival in days 
5. 9, 10,11 •, 12•, 12•, 13, 13,13,14 •, 15• 
6. 5 mg/kg CsA 1 18.,51,54.,72',> 100 
7. 15 mg/kg CsA 1 10,10,17, > 200, >200, > 200, > 200, > 200 
8. 25 mg/kg CsA 1 5,7,10,12,14d,>200 
a: mean survival time ± standard error of the mean 
b: animals exhibited grade 1-2 GVHD 
c: animals exhibited grade 3 GVHD, d: functional ileus of the graft 
e: died with functioning graft 
1: CsA was given on days 0,1,2,4 and 6 
MST±SEa 
12.2±0.6 
41.0±11.5 
>200 
9.6± 1.6 
occurred between days 5 and 7 posttransplant and disappeared after 2 days. The 
administration of 5 mg/kg CsA (group 6) already evoked a significant 
prolongation of graft survival. One animal survived for more than 100 days, 1 
animal died with a functioning graft 72 days after transplantation, and 3 of 5 
animals died after 41.0± 11.5 days. Foutty percent developed a transient grade 1-
2 GVHD. In group 7, 5 of 8 animals survived permanently (>200 days). This 
CsA dose also effectively suppressed GVHD. Treatment with 25 mgjkg CsA 
gave the same MST as in the control group. At autopsy, a dear-cut rejection 
could not be proven, and 1 animal had a functional ileus of the transplant. 
DISCUSSION 
In the difficult WAG to BN combination we were unable to induce donor 
specific unresponsiveness, as is seen when heart or kidney transplants are treated 
with short courses of CsA (Niessen et a!. 1982). Long surviving animals in group 
4 even rejected their grafts 79, 112, and 200 days after cessation of CsA 
maintenance therapy, that was given 3 times a week until day 100. Surprisingly, 
in group 2, 5 animals developed a lethal grade 3 GVHD. This indicates that CsA 
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evoked a disbalance between GVH and rejection in favour of GVH. Apparently, 
CsA is less effective in controlling the GVHD than in controlling rejection, a 
finding reported earlier by Kirkman et al. (1985). The functional ileus seen in 
some animals after higb dose CsA treatment could be a toxic side-effect of CsA 
Very little is as yet known about CsA toxicity on the bowel, but it has been 
shown that CsA may have a deleterious effect on the small bowel 
microvasculature (Crane et al. 1990). 
In the "moderate" BN to WAG combination significant prolongation of graft 
survival was already seen after a short course of 5 mg/kg CsA Treatment with 
15 mg/kg led to permanent survival of 5 of 8 animals, and totally abolished the 
occurrence of GVHD. These results are better than those in group 4 of the 
WAG to BN combination, in which the total amount of CsA given was higher. 
The poor results obtained in the 25 mg/kg group may be due to CsA toxicity. 
Since heart allografted rats tolerate this dose very well (Bouwman et al. 1989) 
this may be a toxic effect on the vulnerable bowel transplant (Crane et al. 1990, 
Table 3. Frequency, grade, and duration of GVHD in the various groups. 
group n GVHgrade GVH grade clinical GVHD 
1-2 3 onset1 end1 
1. 17 6 0 9.5 ± 0.3 12.5 ± 0.9 
2. 14 2 5 18.0 ± 0.8 23.1 ± 2.9 
3. 10 1 1 20.5 ± 2.5 39.0 ± 3.0 
4. 9 2 1 26.0 ± 1.7 34.7 ± 8.2 
5. 10 5 0 6.2 ± 0.4 8.4 ± 0.5 
6. 5 2 0 7.5 ± 1.5 10.5 ± 0.5 
7. 8 0 0 
8. 6 0 0 
1: days after transplantation: mean ± standard error of the mean. 
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Sigalet et a!. 1991). 
We conclude that the effectiveness of CsA is dependent on the rat strain 
combination used, and that the WAG to BN combination is a "bard" SBT model 
which exhibits at least some of the immunological problems seen in large animal 
models. The BN to WAG combination on the other hand, in which permanent 
survival can be easily obtained using CsA as single immunosuppressive agent, 
can be used to study the functional aspects of long surviving animals. 
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PRE- AND POSTOPERATIVE TREATMENT WITH CYCLOSPORJ:NE A 
IN THE MANAGEMENT OF SMALL BOWEL ALLOGRAFT 
REJECTION AND GRAFT-VERSUS-HOST DISEASE 
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SUMMARY 
Long-term survival of small bowel allografts cannot be obtained on a regular 
basis since transplantation is hampered by severe rejection. In the WAG to BN 
rat model we investigated whether pretreatment of the recipient with CsA was 
able to improve the results obtained with postoperative CsA monotherapy. 
Previously we have found that 25 mgjkg CsA given on days 0,1,2,4, and 6 
followed by 15 mgjkg 3 times a week until day 100 led to long-term survival 
( > 100 days) in only 3 of 9 cases. 
Untreated recipients rejected their grafts in 12.8± 1.0 days (mean survival time; 
MST±SE). CsA pretreatment on day -1 prior to transplantation with 50 mgjkg 
combined with a postoperative course of 25 mg/kg on days 0,1,2,4, and 6 Jed to 
a MST of 44± 17 days (n=S). When pretreatment was given on days -9,-7,-5, and 
-3 before transplantation with 25 mg/kg CsA, followed by the same postoperati-
ve course as in the previous group, a MST of 79± 16 days was found. This 
pretreatment schedule, combined with a low-dose long-term course of 5 mgjkg 
CsA on days 0,1,2,4, and 6 after transplantation and subsequently 3 times a week 
until day 100 gave a MST of 116±33 days. Since in some animals a severe graft-
versus-host reaction (GVHD) developed, donors in the next group were irradia-
ted with 5 Gray on the day of transplantation. These grafts, transplanted in 
recipients that received the same CsA treatment as the previous group, were 
rejected in 155 ± 15 days. No GVHD was encountered in this group. Without 
pretreatment, 5 mgjkg CsA given on days 0,1,2,4, and 6 after transplantation and 
subsequently 3 times a week until day 100 gave a MST of 121±29 days. No 
statistically significant differences between these groups were found, although 
only with pretreatment we found consistent long-term survival. 
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INTRODUCTION 
The small bowel is particularly vulnerable to rejection, probably due to the loss 
of its barrier function. Even mild, reversible rejection is accompanied by 
bacterial translocation from tbe graft to the mesenteric lymph nodes and the 
blood. In a recipient that is receiving immunosuppression, and which probably 
has a bacterial overgrowth of its small bowel graft (Browne et al. 1992), this may 
have serious consequences. It is therfore of utmost importance to optimally 
control rejection after small bowel transplantation (SET), in order to maintain 
the gut barrier function. It is thought that cyclosporine A (CsA) is able to act 
satisfactory as mainstay of immunosuppressive regimen following SET (Grant et 
al. 1990, Schroeder et al. 1990). However, experimental results obtained previ-
ously in our laboratory using the WAG to BN rat donor-host combination have 
shown that in this model we were unable to consistently produce long-term 
allograft survival with postoperative CsA monotherapy (Chapter 5, Saat et al. 
1990). Therefore the present study was initiated to investigate whether pretreat-
ment of the recipient with CsA could improve the results obtained with postope-
rative CsA monotherapy in this rat model of SET. 
MATIERIALS AND METHODS 
Animals: rats of the WAG (Rtl ") and BN (Rtl ") strains were used as donors and 
recipients respectively (see chapter 2). 
Small bowel transplantation: transplantation was performed as described in 
chapter 2. In brief, the total small bowel from the ligament of Treitz to the 
terminal ileum was transplanted with its superior mesenteric artery anastomosed 
end to side to the recipient aorta, and its portal vein to the caval vein. The 
recipient small bowel was resected, and the graft was placed orthotopically by 
end-to-end anastomoses with the host's duodenum and remaining 1-2 em of 
terminal ileum. 
GVHD: 3 grades were distinguished, as outlined in chapter 2. 
Cyclosporine A: see chapter 2. 
Irradiation was performed as described in cbapter 2. 
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Histology: terminal ileum of the graft and remnant host ileum were fixed in 3.6% 
buffered formalin. Three to 4 J.<m paraffin sections were cut and stained with 
hematoxylin-phloxine-saffron. 
Statistics: the survival data were statistically analysed using Kruskai-Wallis 
analysis of variance. 
EXPERIMENTAL GROUPS 
Group 1: Controls, no treatment (n=10). 
Group 2: Intramuscular pretreatment with 50 mg/kg CsA 1 day before trans-
plantation, followed by 25 mgjkg CsA im on days 0,1,2,4, and 6 after grafting 
(n=5). 
Group 3: Pretreatment with 25 mgjkg CsA on days -9,-7,-5, and -3 before 
transplantation, followed by 25 mgjkg CsA on days 0,1,2,4, and 6 after trans-
plantation (n=5). 
Group 4: Pretreatment with 25 mgjkg CsA on days -9,-7,-5, and -3 before 
transplantation, followed by 5 mgjkg on days 0,1,2,4, and 6 and subsequently 3 
times a week until day 100 after transplantation (n = 9). 
Group 5: Recipients were treated as in group 4. Additionally, donors were 
irradiated with 5 Gray (Gy) on the day of transplantation (n=5). 
Group 6: No pretreatment, postoperative CsA consisted of 5 mgjkg on days 
0,1,2,4, and 6 and subsequently 3 times a week until day 100 (n=9). 
RESULTS 
Survival and GVHD; 
In a previous study (chapter 5) we found that adntinistration of CsA 25 mgjkg 
on day 0,1,2,4, and 6 followed by 15 mg/kg 3 times a week until day 100 led to a 
mean survival time (MST±SE) of 92.6±36.2 days. In the present study, untrea-
ted recipients died from rejection in 12.8± 1.0 days (Table 1). In group 2, CsA 
pretreatment on day -1 prior to transplantation with 50 mgjkg combined with a 
postoperative course of 25 mg/kg on days 0,1,2,4, and 6 led to a MST of 44±17 
days. One animal in this group developed mild, grade 1-2 GVHD and 1 had 
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Table 1. Effect of rec1p1ent-pretreatment with cyclosporine on small bowel 
allograft survival in the WAG to BN donor-host combination. 
recipient treatment 
pretreatment post-Tx 
1. 
25 mg/ki'+ 
15 mg/kg 
2. 50 mg/kg, d-1 25 mgjkg' 
3. 25 mg/kg, 25 mgjkg' 
d-9,-7,-5,-3 
4. 25 mg/kg, 5 mg/kg' 
d-9,-7,-5,-3 
5. 25 mg/kg, 5 mg/kg' 
d-9,-7,-5,-3 + 
5 Gy donorirr d 0 
6. 5 mg/kg' 
survival 
in days 
6,10'11,12,14', 
14,1.5",15,15, 16 
8,12,19,26',27, 
51,179,212,300 
12,15,23',85',86 
49',65',67, 71,143 
12,14,24,35c,lll c, 
186,194,204,269' 
131,131,149,153, 
211 
6,6,16,145,154 
170,178,187,230 
mean:tSE 
12.8:t 1.0 
92.6 :t 36.25 
44:t17 
79:t 16 
116:t33 
155:t 15 
121:t29 
%GVHD1 
40 
11 
40 
40 
33 
0 
0 
1: percentage of animals showing clinical GVHD. a: grade 1; c: grade 3. 
2: cyclosporine 25 mg/kg was given intramuscularly on days 0,1,2,4, and 6, 
followed by 15 mg/kg 3 times a week until day 100. 
3: cyclosporine was given intramuscularly on days 0,1,2,4, and 6 after transplan-
tation. 
4: cyclosporine was given intramuscularly on days 0,1,2,4, and 6 after 
transplantation and subsequently 3 times a week until day 100. 
Kruskal-Wallis one-way ANOV A analysis found no statistical differences 
between groups 2,3,4,5, and 6. 
5: This group has been previously published in chapter 5. 
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grade 3 symptoms (Table 2). When pretreatment was given on days -9,-7,-5, 
and -3 before transplantation with 25 mg/kg CsA, followed by the same post-
operative CsA course as in group 2, a MST of 79 :t 16 days was found. Two of 5 
animals developed severe grade 3 GVHD. In group 4, this pretreatment schedu-
le, combined with a low-dose long-term course of 5 mgjkg CsA on days 0,1,2,4, 
and 6 after transplantation and subsequently 3 times a week until day 100 gave a 
MST of 116:t33 days. Since in this group also some animals developed severe 
GVHD, in group 5 the donors were irradiated with 5 Gray on the day of 
transplantation. These grafts, transplanted in recipients that received the same 
CsA treatment as the previous group, were rejected in 155 :t 15 days. No GVHD 
was encountered in this group. 
Table 2. Percentage of animals surviving beyond 100 days. 
group percentage 
1. 0% 
2. 0% 
3. 20% 
4. 55% 
5. 100% 
6. 66% 
Without pretreatment, 5 mg/kg CsA given on days 0, 1,2,4, and 6 after transplan-
tation and subsequently 3 times a week until day 100 gave a MST of 121:t29 
days (group 6). By using Kruskal-Wallis one-way ANOVA it appeared that the 
experimental groups did not differ significantly among each other. However, 
when comparing the number of animals surviving beyond 100 days, it appeared 
that only in group 5 all animals lived for more than 100 days (Table 2). 
Chronic rejection; 
1n most long-term surviving recipients in the experimental groups, the cause of 
death was malnourishment due to chronic rejection of the small bowel trans-
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plant. The process of chronic rejection was characterized by an initial normal 
postoperative course; weight loss in the first 2 weeks was followed by a gradual 
Fig. la. 
Fig. lb. 
~b~o~d~y_w~e~i~g~h~t~%~-----------------------------120' 
110 
100 
90 
80 
70 
60 
5o~~~-L~-L~~~L_~~-L_L-L-L~~~L_~ 
0 1 2 3 4 5 6 7 8 9 10 12 14 16 18 20 
weeks after transplantation 
rb~o_d~y_w_e~i~g~h_t_%~-----------------------------160 
150 
140 
130 
120 
110 
100 
90 
0123456789m • M m mBa M n 
weeks after transplantation 
Fig. JA: Weight curves of recipients pretreated with 25 mgjkg cyclosporine on days -
9,-7,-5, and -3 before transplantation followed by 25 mgjkg on days 0,1,2,4,and 6 
after transplantation (group 3), and 1B: recipients pretreated with 25 mgjkg 
cyclosporine on days -9,-7,-5, and -3 before transplantation, followed by 5 mgjkg on 
days 0,1,2,4, and 6 and subsequently 3 times a week until day 100. Additionally, 
donors were irradiated with 5 Gray on the day of transplantation (group 5). t: 
cessation of cyclosporine therapy. 
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increase in weight. Subsequently, at various time points for each individual after 
transplantation, the animals started to lose weight (Figs. 1a & 1b ). This weight 
loss could progress rapidly, leading to the death of the animal in a short while 
following its onset, or animals could show a gradual but progressive loss of 
weight. Surprisingly, their clinical appearance was normal. The typical advanced 
stage of chronic rejection showed a thin, but lively animal with diarrhea. At 
autopsy, the transplant appeared thick-walled and fibrotic. Histopathologically, 
moderate to severe villus athropy with mild fibrosis of the muscularis and 
thickening of the serosa was seen. 
DISCUSSION 
1n the WAG to BN rat model of SBT we have previously shown that long-term 
survival of small bowel allografts is hard to obtain using CsA monotherapy 
(Chapter 5). Rejection even occurred after the cessation of long-term CsA 
therapy given until 100 days posttransplant. We therefore concluded that this 
model exhibits at least some of the immunological problems seen in large animal 
models. 
1n the present study we investigated whether pretreatment of the recipient with 
CsA could improve these results. Pretreatment with CsA is associated with a 
reduced incidence of acute rejection in human kidney transplantation (Hong et 
al. 1991). On the other hand, low CsA plasma levels in the early postoperative 
period are associated with a higher incidence of rejection (Kahan et aL 1984, 
Rogerson et al. 1986). Aeder et aL (1991) showed that pretreatment with CsA 
led to a mitigation of the rejection process compared with CsA therapy begin-
ning at the time of transplantation using a dog model of SBT. Pretreatment of 
the recipient has also been shown to be effective in prolonging heart xenograft 
survival in the hamster to rat model (Bouwman et al. 1992). 
We were unable to prolong graft survival significantly as compared with post-
operative treatment alone. Moreover, pretreatment was associated with the 
occurrence of severe GVHD. However in group 5, although not statistically 
significant, uniform long-term graft survival was found. In this group only, all 
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animals survived beyond the duration of the CsA therapy and no acute rejection 
or GVHD were seen. Whether this is due to CsA pretreatment combined with a 
reduction of the immunogenicity of the graft and prevention of clinical GVHD 
by irradiation of the donor should be investigated further. This could be studied 
by using markers of gut permeability, such as 51Cr-EDTA (Grant et al. 1991), or 
lactulose-mannitol (Sigalet et al. 199lb), both parameters of gut permeability and 
early rejection (Grant et al. 1991). 
Taking into account the results obtained in chapter 5, and the findings from the 
present study, it may be speculated that postoperative administration of high 
dose CsA is detrimental to the survival of small bowel allografted rats. In the 
present study we found long-term graft survival after low-dose CsA administrati-
on, that did not differ significantly from the survival obtained in animals pretre-
ated with CsA and/ or high dose postoperative CsA. This hasn't been studied 
before since higher doses of CsA did not consistently produce long-term survi-
vors. It may well be that we have overdosed CsA postoperatively, leading to 
toxicity on the small bowel transplant which negatively influenced graft survival. 
Earlier studies have demonstrated that relatively low doses of CsA are toxic to 
the bowel, since they compromize the transmural microvasculature (Crane et al. 
1990). CsA also affects glucose and fatty acid uptake of normal bowel (Sigalet et 
a!. 1991'), and may increase intestinal permeability in both native and transplan-
ted bowel (Sigalet et aL 1991b). Pretreatment, however, does not seem to have 
such an adverse effect. 
CsA therapy in all groups seemed ineffective against chronic rejection although 
it cannot be excluded that prolonging CsA courses beyond 100 days could 
prevent it. It seems plausible that, as with other organ grafts, long-term small 
bowel-graft function is jeopardized by this as yet uncontrollable and irreversible 
process (Tilney et a!. 1991). 
Considering all results we have obtained with CsA in this model, it appears that 
postoperative courses of low dose CsA with or without graft irradiation, and 
maybe pretreatment of the recipient with CsA, are of benefit to the long-term 
survival of small bowel allografts. 
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SUMMARY 
The effects of pretransplant donor-specific blood transfusion (DST) on the 
survival of orthotopic small bowel transplants in rats were investigated in the 
fully allogeneic BN (Rtln) to WAG (Rtl") donor-host combination. Previous 
studies show that in this combination DST lead to permanent survival of 
heterotopically transplanted hearts, marked prolongation of kidney grafts, and 
moderate prolongation of pancreas grafts but have no effect on skin grafts. 
Without pretreatment, total small bowel grafts ( :!:45 em) were rejected in 
12.2± 1.8 days (mean±SD), and 10-cm segments of jejunum or ileum in 11.2:!:4.0 
and 11.6±0.5 days, respectively. Three DST given on days -21, -14, and -7 before 
transplantation had no effect on graft survival in any of the groups tested. Total 
small bowel grafts were rejected in 12.8±2.5 days, and 10-cm long segments of 
jejunum or ileum in 17.0:!:7.2 days and 11.5:!:2.7 days, respectively. Graft-versus-
host disease (GVHD), which was mild and transient, occurred in 50% of the 
nontreated rats engrafted with a total small bowe~ in 40% of the animals 
transplanted with an ileum segment, and in none of the rats that received a 
jejunal transplant. In the DST- pretreated groups, none of the animals 
transplanted with a total small bowel or ileum segment and 16.6% of the animals 
transplanted with a jejunum segment showed clinical signs of GVHD. When 
DST pretreatment was combined with cyclosporine A (CsA) grafts did not 
survive any longer than with CsA treatment alone. It is concluded that DST 
ameliorate GVHD, but do not prolong the survival of small bowel allografts nor 
act additively with CsA treatment. 
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INTRODUCTION 
The resurgence of interest in small bowel transplantation (SBT) as a treatment 
for the short bowel syndrome is largely due to the impressive results obtained 
with cyclosporine A (CsA) in clinical organ transplantation. In several smdies on 
SBT, CsA was the main immunosuppressive agent used. In general, it appears 
that in large animal models (dog and pig) long term survival can only be 
achieved using high dosages of CsA (Fujiwara et a!. 1987, Grant et a!. 1988). 
Even in some rat models long-term survival is hard to obtain (Saat et al. 1990). 
In a recent clinical SBT, it was not possible to prevent acute rejection of the 
graft in 13 days, in spite of agressive quadruple therapy, which gave rise to 
serious side effects (Grant et al. 1989). Other attempts of clinical SBT have also 
failed to yield long-term surviving grafts with good function (Grant, 1989). 
Apparently, small bowel grafts are vigorously rejected, and there is an urgent 
need for adequate immunosuppression. 
Pretransplant donor-specific blood transfusions (DST) may lead to a 
prolongation of allograft survival in both experimental (Marquet et al. 1971) and 
clinical (Opelz et al. 1973) transplantation. The mechanisms underlying this well-
known phenomenon are still not fully elucidated, but suppressor cells (Singh et 
a!. 1987), anti-idiotypic antibodies (Phelan et al. 1989), clonal deletion of 
cytotoxic T-cell precursors (van Twuyver et al. 1989), and metabolites of 
arachidonic acid (Perez et al. 1989) have all been shown to be involved, 
depending on the model used. 
Previous smdies in our laboratory have shown that DST induce T-suppressor 
cells, leading to permanent heart graft acceptance and marked prolongation of 
kidney graft survival. This induction of donor-specific unresponsiveness would be 
one way to improve the results of SBT. Reduction of the immunogenicity of the 
graft by reducing its length, i.e., transplantation of a segment of 15-30% of the 
total length of the small bowel offers another avenue to approach the problem 
of ameliorating rejection (Kimura et al. 1987). 
The present study was undertaken to investigate the effect of DST on the 
survival of small bowel grafts, varying in length and site of origin, and to 
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evaluate the effect of CsA in combination with DST in a fully allogeneic donor-
host combination. 
MATERIALS AND METHODS 
Animals: rats of the inbred BN (Rtl •) and WAG (Rtl u) strains were used as 
described in chapter 2. 
Blood transfusions: 1 ml of heparinized whole blood was administered 
intravenously on days -21, -14 and -7 prior to transplantation. 
Small bowel transplantation: orthotopic total SBT was performed as described in 
chapter 2. Briefly, the total small bowel, from the ligament of Treitz to the 
terminal ileum was harvested along with its vascular pedicle, consisting of the 
portal vein and superior mesenteric artery. In the recipient the infrarenal aorta 
and inferior caval vein were clamped, and end~to~side anastomoses were 
performed between the recipient aorta and caval vein and donor superior 
mesenteric artery and portal vein, respectively. The recipient small bowel was 
resected and the graft was anastomosed proximally with the host's duodenum 
and distally with the remaining terminal ileum. 
Jejunal transplants consisted of 10 em of proximal jejunum. ileal grafts were 
prepared by isolating 10 em of distal ileum from the small boweL 
Postoperative monitoring: as described in chapter 2. In this study only grade I 
GVHD (light redness of snout, ears and paws) was observed. 
Cyc/osporine A: (Sandimmune, Sandoz, Basel, Switzerland) was dissolved in oil to 
a concentration of 25mg/ml and administered intramuscularly (i.m.) in a volume 
of 0.1-0.2 ml. 
Statistics: Wilcoxon rank-sum test and the chi-square test were used for statistical 
analysis of the data. 
EXPERIMENTAL GROUPS 
EN rats were used as donors and WAG rats as recipients, except in the syngeneic 
group (2) in which WAG rats were used both as donor and as recipient; 
Group 1: Control group; transplantation of total small bowel (45 em). No pre, or 
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postoperative treatment (n= 10). 
Group 2: Control group, syngeneic transplantation of 10 em of proximal jejunum 
(n=3). 
Group 3: Transplantation of 10 em proximal jejunum, no treatment (n=6). 
Group 4: Transplantation of 10 em distal ileum, no treatment (n=5). 
Group 5: Total small bowel graft ( 45 em), recipient pretreated with 3 DST 
(n=9). 
Group 6: Transplantation of 10 em proximal jejunum, recipient pretreated with 3 
DST (n=6). 
Group 7: Transplantation of 10 em distal ileum, recipient pretreated with 3 DST 
(n=8). 
Group 8 : Total small bowel graft, recipient treated with 5 mgjkg CsA i.m. on 
days 0, 1, 2, 4 and 6 after grafting (n=5). 
Group 9: Transplantation of total small bowel, recipient pretreated with 3 DST 
and 5 mg/kg CsA on days 0, 1, 2, 4 and 6 after grafting (n=4). 
RESULTS 
Survival times of different segments, no treatment 
The animals in group 1 rejected their grafts between 9 and 15 days, with a mean 
survival time (MST±SD) of 12.2± 1.8 days. Animals transplanted with a 10-cm 
jejunal or ileal segment (groups 3 and 4) rejected their grafts with a MST of 
11.2±4.0 and 11.6±0.5 days, respectively. This is not significantly different from 
group 1. There was however a difference in the occurrence of GVHD. In group 
1 50%, and in group 4 40% of the rats developed a mild transient grade I 
GVHD. The onset of clinical GVHD was between days 5 and 11 posttransplant 
and lasted for approximately 3 days. The group grafted with the jejunal 
transplants (group 3) showed no signs of GVHD (p<0.05, chi-square test)(Table 
1). 
Effects of DST 
Pretransplant adntinistration of 3 DST had no significant effect on graft survival, 
neither in the total small bowel transplanted group, nor in the jejunal- or ileal-
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Table 1. Survival times of various segments of small bowel transplants. 
group survival in days MST:!: SD1 
1. BN to WAG 9, 10,11 ', 12a, 12', 13, 13,13, 14', 15a 12.2:!:1.8 
2. WAGtoWAG >100,>100,>100 
jejunal graft 
3. BNtoWAG 6,9,10,12,12,18 11.2:!:4.0 
jejunal graft 
4. BNto WAG 11,11',12',12,12 11.6:!:0.5 
ileal graft 
1: mean survival time ± standard deviation 
2: percentage of animals showing clinical signs of GVHD. 
a: animals showing clinical signs of GVHD. 
%GVHD2 
50% 
0% 
40% 
engrafted groups. The MST of the pretreated animals that received a total small 
bowe~ a jejunal, or an ileal segmental graft were 12.8±2.5, 17.0±7.2, and 
11.5:!:2.7, respectively (Table 2). 
A significantly smaller number of rats in the transfused groups showed clinical 
signs of GVHD (p < 0.05, group 1 versus groups 5 and 7). In groups 5 and 7 none 
of the rats, and in group 6 one rat (16.6%) exhibited a grade I GVHD. 
Effects of DST and CsA 
A short course of CsA led to significantly prolonged survival times in comparison 
with untreated, or DST treated animals. In group 8, 3 out of 5 animals died with 
an MST of 40.1 ±20.0 days; 1 animal died 72 days after transplantation with a 
functioning graft, and 1 animal survived beyond 200 days. Survival times in 
animals receiving the combination of pretransplant blood transfusions with a 
posttransplant course of CsA (group 9) did not differ significantly from those 
obtained in group 8; 3 out of 6 animals died with an MST of 26.7±3.2 days, and 
3 out of 6 animals survived for more than 100 days (Table 2). In group 2 WAG 
rats transplanted with a syngeneic, 10-cm long small bowel graft thrived well and 
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Table 2. Effect of donor-specific blood transfusions and cyclosporine A on graft 
survival. 
group survival in days MST:tSD1 %GVHD2 
5. 3XDST3 10, 10, 11, 12, 12, 14, 14, 14,18 12.8:!:2.5 O%' 
6. 3XDST3 7,14,15,15,253 ,26 17.0:!:7.2 16.6% 
jejunum segment 
7. 3X DST3 6,9, 11, 13, 13, 13, 13,14 11.5:!:2.7 O%' 
ileum segment 
8. CsA4 18',51,54',725, >200 >79.6:>:70.3 40% 
9. DST3+CsA4 23,28',29, > 200, > 200, > 200 > 113.3:!: 95.0 16.6% 
1: mean survival time :!: standard deviation 
2: percentage of animals showing clinical signs of GVHD 
3: donor-specific blood transfusions: 1 ml of heparinized whole blood was given 
intravenously on days -21,-14 and -7 before transplantation 
4: Cyclosporine A was given intramuscularly on days 0, 1,2,4 and 6 after grafting 
at a dose of 5 mg/kg. 
5: died with functioning graft 
6: p < 0.05 versus group 1, Chi-square test 
a: animals showing clinical signs of GVHD 
showed a steady increase in weight (Table 1). 
DISCUSSION 
Theoretically, segmental grafts have immunological advantages over total small 
bowel grafts: both the number of immunocompetent cells transplanted and the 
organ-specific antigenic load are reduced, thus ameliorating GVHD and 
rejection. In this study no beneficial effect of length reduction on the rejection 
process could be demonstrated. This is in accordance with results obtained by 
Kimura et a!. (1987), and Stangl et a!. (1989) who also found no differences in 
graft rejection times, irrespective of the length or the site of origin of the graft. 
In rats transplanted with a jejunal segment, which includes a short segment of 
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the mesentery and only about 50% of the mesenteric lymph nodes as compared 
to a total small bowel or an ileal graft, no GVHD occurred. In 50% of the rats 
grafted with a total bowel and 40% of the animals transplanted with an ileum 
segment, clinical GVHD developed. This is in contrast to observations made by 
Kimura et al. (1987) who found no relation between the length or the segment 
of bowel that was transplanted, and the occurrence of GVHD. 
In this study, donor-specific blood transfusions had no effect on graft survival in 
any of the groups tested. Previous studies in our laboratory have shown that DST 
in this model lead to permanent heart graft survival (Marquet et al. 1971), 
marked prolongation of kidney graft survival (Marquet et al. 1971), and very 
moderate prolongation of pancreas graft survival (Spillenaar-Bilgen et al. 1990) 
but have no effect on skin graft survival (Marque! et al. 1971). DST-induced T-
suppressor cells are involved in this model that can impose unresponsiveness 
upon naive recipients (Singh et al. 1987). Possibly, segmental grafts of 20% of 
the small bowel are still highly immunogenic and a further decrease in antigenic 
load is mandatory to allow the blood transfusion effect to emerge. 
An alternative explanation is that the immunogenicity of the graft is effectively 
reduced, but that the bowel is more vulnerable to rejection than heart or kidney 
grafts, which are able to withstand rejection episodes. 
Surprisingly, significantly fewer rats in the DST-pretreated groups showed clinical 
signs of GVHD as compared to the control groups. This finding implies that 
DST may have induced some form of immunosuppression, reflected in the 
abscence of GVHD, but not in the survival time, again an indication for the 
vulnerability of the graft. Rolstad (1976) has shown that recipient cells are 
required for the development of a GVH reaction in a parent to F1 one-way 
model, and he postulated that these cells contributed to the GVH reaction by 
secreting ntitogenic and blastogenic factors. In our model, a DST-induced 
alteration of the recipient responsiveness may have contributed to the abscence 
of clinical GVHD. 
Five mg/kg CsA given on days 0,1,2,4 and 6 after grafting significantly prolonged 
graft survival. Using tltis treatment schedule 60% of the animals showed 
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prolonged survival, while 40% survived permanently. Consequently, it should be 
possible to obtain improved graft survival when additional treatment would act 
additively or synergistically. We found no positive effects of combined treatment 
with DST and CsA on graft survival. Martinelli et a!. (1988), who also found no 
effect of DST on small bowel allograft survival, did find a synergistic effect of 
DST combined with low dose CsA This difference may be explained by the 
different donor-host combination used. They used the ACI to l.ew combination, 
starting with CsA on the day of transfusion, and proceeding with low-dose CsA 
until 30 days after transplantation. 
From our data we conclude that preconditioning with DST ameliorates GVHD, 
and does not have a beneficial effect on the survival of small bowel allografts. 
Combined DST and CsA treatment does not improve the outcome of graft 
survival in the model employed. These data suggest that preoperative donor-
specific blood transfusions have no effect on small bowel transplant survival 
using these inbred strains of rats. 
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SUMMARY 
Multiple studies have demonstrated that FK-506 is effective in preventing the 
rejection of cardiac, renal, and hepatic allografts. Although it is shown that 
rejection and graft-versus-host disease (GVHD) following small bowel 
allografting are also suppressed by FK-506, additional studies are needed to 
determine the role for FK in small bowel transplantation (SET). We studied the 
effectiveness of FK-506, as compared to cyclosporine A (CsA), as an 
immunosuppressant in small intestinal transplantation. Fully-allogeneic-total-
orthotopic-SET was performed in the WAG to EN donor-host rat combination. 
Control animals died from rejection with a mean survival time (MST) of 
12.8± 1.0 days, (group 1, n= 10), 40% of the animals exhibited a mild, transient 
GHVD (grade 1-2) consisting of mild redness of ears, snout, and paws. 
CsA 15 mg/kg given intramuscularly on days 0, 1,2,4, and 6 after grafting gave a 
MST of 61.4±4.1 days (group 2, n=5), none of the animals showed clinical 
GVHD. 
FK-506, 2 mg/kg given on days 0,1,2,4, and 6 after grafting gave a MST of 
28.5±6.8 days, (group 3, n=8). 88% of the animals had severe clinical GVHD, 
consisting of severe redness of ears, snout and paws, inflamed neck, and bunched 
posture. Although in some animals clinical signs of GVHD subsided, 
histopathologic examination revealed severe GVHD-like lesions at the time of 
death. Other animals died during clinical GVHD. 
Additional treatment with 5 Gray donor-irradiation on the day of transplantation 
abolished clinical GHVD completely, but did not lead to prolongation of graft 
survival when compared to FK treatment alone, (group 4, n=7, MST 27.6±2.4 
days). 
This study shows that FK is less effective in controlling GVHD than in 
controlling rejection. The most striking finding however is that FK-506 treatment 
allows the development of previously unseen fulminant GVHD. This finding may 
have important impications for its use in clinical SET. 
110 
FK-506 
INTRODUCTION 
Since its discovery in 1984 (Kino et al. 1987), the macrolide FK-506 has been 
shown to be a potent innnunosuppressive drug in experimental and clinical organ 
transplantation (Thomson, 1990). Whereas the effects of FK-506 in heart, kidney, 
and liver transplantation have been thoroughly investigated, its effects on 
experimental small bowel transplantation (SBT) remain relatively unexplored. 
Results obtained in SBT with cyclosporine A (CsA) are poor (Marquet & 
fugham-Clark 1991), and rejection remains the limiting obstacle. Better 
immunosuppressive drugs may give new impetus to clinical SBT. The present 
study was undertaken to compare the effects of FK-506 and CsA on rejection 
and graft-versus-host disease (GVHD) after fully-allogeneic SBT in rats. 
MATERIALS AND METHODS 
Animals: rats of the inbred WAG (Rtl ") and BN (Rtl ") strains were used as 
donors and recipients respectively, as described in chapter 2. 
Small bowel tro:nsplantation: was performed as described in chapter 2. In brief, 
the total small bowel was harvested from the ligament of Treitz to the terminal 
ileum, along with a vascular pedicle consisting of the superior mesenteric artery 
and portal vein. In the recipient the infra-renal aorta and caval vein were 
clamped and end-to-side anastomoses were performed between the recipient 
aorta and caval vein and the donor superior mesenteric artery and portal vein 
respectively. The recipient small bowel was resected, and the graft was placed in 
an orthotopic position by end-to-end anastomoses proximally with the host's 
duodenum and distally with the remaining 1-2 em of terminal ileum. 
Post-operative monitoring: after surgery, animals received standard laboratory rat 
chow and water ad libitum. The animals were weighed 3 times a week and were 
inspected daily for signs of clinical GVHD. Three grades of GVHD were 
distinguished. Grade 1: light redness of ears, snout and paws. Grade 2: moderate 
redness of ears, snout ans paws, light hair-loss and diarrhea. Grade 3: severe 
redness of ears, snout and paws, alopecia, generalized dermatitis and diarrhea. 
Rats that died within 4 days from transplantation were considered technical 
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failures. After death, autopsy and histologic examination were performed. 
Cyclosporine A: commercially available CsA (Sandimmune, Sandoz, Basel, 
Switzerland) was obtained and diluted in olive oil to a concentration of 50 
mg/ml before intramuscular administration. 
FK-506: FK-506 was a gift from the Fujisawa Pharmaceutical Co, Osaka, Japan. 
FK-506 was dissolved in absolute methanol, and subsequently diluted 10 times in 
olive oil to a concentration of 5 mgfml. 
Histology: the following tissues of the recipients were sampled for histopathologic 
analysis: terminal ileum of grafted bowel, remnant ileum of recipient, thymus, 
submandibular salivary gland, liver, spleen, mesenteric-, cervical-, and axillary 
lymph nodes, lip, and ear. These tissues were fiXed in 3,6% buffered formalin. 
Three to 4 Jl.ID paraffin sections were cut and stained with hematoxylin-phloxine-
saffron. 
EXPERIMENTAL GROUPS 
The following groups were studied in the fully-allogeneic WAG to BN model; 
Group 1: Control group, no immunosuppressive therapy, n = 10. 
Group 2: Recipients were treated with 15 mg/kg CsA on days 0, 1, 2, 4, and 6 
after transplantation, n=5. 
Group 3: Recipients were treated with 2 mg/kg FK-506 on days 0, 1, 2, 4, and 6 
after grafting, n = 8. 
Group 4: Recipients received FK-506 as group 3, additionally donors were 
irradiated with 5 Gray on the day of transplantation, n=7. 
RESULTS 
Graft survival and clinical GVHD 
Untreated recipients in group 1 died from rejection in 12.8± 1.0 days (mean 
survival time, MST ± standard error of the mean, SE) (Table 1). Fourry percent 
of the animals had a mild transient GVHD (grade 1-2) that usually became 
visible on day 9 posttransplant, and lasted approximately 3 days. 
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Table 1: Effect of FK-506 on rejection and GVHD following orthotopic total 
small bowel transplantation in the WAG to BN rat model. 
treatment survival in days MST:tSE %GVHD• 
CsA 15 mgfkg' 
FK-506 2 mg/kg' 
5 Gy donor irr + 
FK-506 2 mg/kg' 
6,10',11, 12, 14',14,15', 
15,15,16 
48,59,60,69,71 
20,21 b,21 b ,21 b,22b,23b, 
24b,76b 
21,23,25,26,28,30,65 
a: animals showed mild (grade 1-2) clinical GVHD 
b: animals had severe (grade 3) GVHD 
12.8:t 1.0 
61.4:!:4.1 
28.5 :!:6.8 
31.1:!:5.7 
c: cyclosporine A (CsA) and FK-506 were given intramuscularly on days 
0,1,2,4, and 6 after transplantation 
d: percentage of animals showing clinical GVHD 
40 
0 
88 
0 
CsA 15 mg/kg, given on days 0, 1, 2, 4, and 6 after transplantation (group 2) led 
to a MST of 61.4:t4.1 days. None of the animals showed clinical signs of GVHD. 
FK-506 treatment (group 3) gave significantly shortened survival times when 
compared to CsA treatment. Although acute rejection did not occur in this group 
the MST :t SE was 28.5 :t 6.8 days. Seven out of 8 animals developed severe 
clinical (grade 3) GVHD (Table 2). These animals not only developed a severe 
redness of ears, snout, and paws, but also had a severely inflamed ventral neck 
region, a hunched posture, and tip-toed on their hind legs. In most animals 
clinical GVHD started between day 13 and 16 posttransplant, and lasted until 17 
to 25 days posttransplant. Donor-pretreatment with 5 Gray gamma-irradiation on 
the day of transplantation completely abolished clinical and histologic GVHD. 
The MST was 3Ll:t5.7 days, which was not significantly different from FK-506 
treatment alone. 
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Table 2: Rejection and graft-versus-host disease after FK-506 treatment. 
survival clinical GVHD1 histological GVHD2 histological cause of 
days days posttx at time of death rejection death 
20 nd nd eci 
21 16- 19 severe minimal3 GVHD 
21 16- nd nd rejection (macroscopically) 
21 13- 17 mild severe rejection (histologically) 
22 16-22 moderate minimal GVHD 
23 6-23 nd nd rejection (macroscopically) 
24 13- 24 moderate minimal severe pneumonia 
76 15-25 none chronic mild chronic rejection 
FK-506 was given at a dose of 2 mgjkg on days 0, 1, 2, 4, and 6 after grafting. 
nd = not done. 
1: all animals had severe clinical GVHD, characterized by severe redness of 
ears, snout, paws, and a severely inflamed ventral neck region. 
2: histologic GVHD was characterized by dermatitis of the skin of ear and lip, 
infiltration of the portal triads of the liver, apoptosis of few bile ductular 
epithelial cells, few apoptotic salivary gland duct epithelial cells, and depletion of 
lymphocytes in thymus and spleen. Moderate and mild GVHD lesions were 
limited to the skin of ears and lip. 
3: there was minimal evidence of graft rejection, characterized by scattered 
apoptosis of crypt epithelial cells. 
Histology 
Lesions of severe GVHD were characterized by marked acanthosis of the 
epidermis of ears and lip with scattered dyskeratotic keratinocytes. The dermis 
was infiltrated by a moderate number of macrophages and lymphocytes mixed 
with few neutrophils. Portal triads of the liver were infiltrated by a moderate 
number of mononuclear cells and there was apoptosis of a few bile ductular 
epithelial cells. A few apoptotic epithelial cells were seen in the submandibular 
salivary gland duct epithelium. Moderate and mild GVHD lesions were less 
severe and limited to the skin of ears and lip. The thymus was depleted of 
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lymphocytes. There was necrosis and depletion of lymphocytes in the splenic 
white pulp and lymph nodes. Animals with GVHD had minimal evidence of 
graft rejection, characterized by apoptosis of scattered crypt epithelial cells. After 
donor pretreatment no signs of histologic GVHD could be demonstrated, all 
grafts were rejected. 
DISCUSSION 
Most studies on the immunosuppressive capacities of FK-506 have showo that it 
is a highly potent agent in preventing allograft rejection. Hoffman et a!. (1990), 
performed an extensive study on the use of FK-506 for small intestine 
transplantation in rats, and found that long courses of FK-506 are more effective 
than CsA in the prevention of acute rejection and lethal GVHD in one-way 
Parent to F1-hybrid models. Shan courses of 2 mg/kg given on days 0-6 were 
effective in preventing rejection in a fully-allogeneic model and the survival 
times were significantly longer than after CsA treatment. No clinical GVHD was 
observed. 
In our study, we were unable to find superior immunosuppressive effects of FK-
506 over CsA Graft survival after a shon course of FK-506 was significantly 
worse when compared to CsA treated animals. Moreover, FK-506 permitted the 
development of severe clinical GVHD, with the corresponding histopathologic 
lesions including dermatitis and lymphoid depletion of thymus and spleen. After 
donor-irradiation no clinical GVHD was observed, but this had no effect on graft 
survival. The immunosuppressive effects of mild GVHD we observed in earlier 
studies (Saat et a!. 1989) did not occur after FK-506 treatment. The observed 
GVHD was clearly harmful to the recipient. 
Taken together the severe GVHD that follows FK-506 treatment in our model, 
and the recent findings indicating that FK-506 may accentuate heart graft 
coronary disease (Arai et a!. 1991), one of the main lesions of chronic rejection, 
we feel there is reason to stay cautious about the use of FK-506 as mainstay of 
future immunosuppressive protocols in SBT. 
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SUMMARY 
Although clinical small bowel transplantation (SBT) is still severely hindered by 
rejection of the graft, prolonged graft survival can be achieved using cyclosporine 
A (CsA) in several experimental models of SBT. In an immunologically 
quiescent phase after transplantation, the important question arises whether a 
small bowel (SB) allograft has enough functional capacity to maintain a normal 
nutritional status. We investigated the functional capacity of orthotopic SB 
transplants, and evaluated the ability of the total small bowel transplant to 
absorb orally given CsA in the early postoperative period, and the effect of this 
oral CsA treatment on allograft survival as compared to intramuscular 
administration. Between 3 and 7 months postoperatively, recipients of syngeneic-, 
and allogeneic total SB transplants and as syngeneic jejunal segmental grafts had 
significantly decreased serum triglyceride levels. Total serum protein and 
albumin concentrations, serum cholesterol values, fecal fat excretion, and 
percentage of split fatty acids were normal. One year after transplantation weight 
in the groups transplanted with a total SB graft was not different from age-
matched untreated controls. Animals grafted with a segmental graft, however, 
showed a significantly impaired growth and had not reached a normal weight 1 
year after transplantation. Growth was also significantly impaired after near-total 
SB resection. These animals had to be killed because of their poor condition. 
CsA absorption after SET equalled that in normal controls. Graft survival after 
intramuscular treatment was significantly better than after oral treattnent. 
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INTRODUCTION 
Small bowel transplantation (SBT) would be the therapy of choice for patients 
with the short bowel syndrome. These patients are now being treated with total 
parenteral nutrition. Although great improvements have been made with the use 
of this life support system, problems such as recurrent catheter sepsis, thrombosis 
of veins, and liver damage will eventually result in patient morbidity and 
mortality (Grosfeld et a!. 1986). For these patients a safe SET would greatly 
enhance the quality of life or could even be life-saving. 
Clinical SET is still severely hampered by rejection of the graft; of several 
recently transplanted patients only few have a long-term functioning graft 
(Schroeder et a!. 1990). At the moment clinical SET can not be considered as a 
true therapeutic option (Watson & Lear 1989). Although several experimental 
studies on the function of small bowel grafts have been performed, there is as 
yet no conclusive answer as to whether a total small bowel graft has enough 
ftmctional capacity to maintain a normal nutritional status, or to sustain normal 
growth and development in juvenile subjects. This question becomes even more 
urgent when segmental SET is considered. In living-related transplantation, in 
which only partial resection of the donor bowel is possible, and paediatric 
transplantation in which there is size dissimilarity in abdominal space between 
donor and acceptor, or in attempts to reduce graft-versus-host-disease, segmental 
transplantation would be the treatment of choice. 
Changes in the function of the graft can be anticipated because of the transplant 
procedure itself, and the immunological processes which will take place. It is 
thought that cyclosporine A (CsA) therapy after transplantation should be given 
parenterally instead of orally because of the impaired capacity of the disrupted 
lymphatics of the transplant to absorb fat and fat soluble substances (Schraut, 
1988). The aim of the present study was to investigate the effects of ischaemia, 
neural-, and lymphatic division as a result of the transplant procedure, and of 
rejection damage as a result of allogeneic transplantation on the function of 
small bowel grafts. Secondly, we investigated whether a transplant is able to 
absorb orally given CsA, and what effect this route of administration has on graft 
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survival as compared to intramuscular treatment. 
MATERIALS AND METHODS 
Animals: rats of the inbred BN (Rtln) and WAG (Rtlu) strains were used as 
described in chapter 2. 
Small bowel transplantation: SBT was performed as described in chapter 2. In 
brief, the total small bowel was harvested from the ligament of Treitz to the 
terminal ileum, along with a vascular pedicle consisting of the superior 
mesenteric artery and portal vein. Segmental grafts consisted of :!: 10 em of 
proximal jejunum. In the recipient the infrarenal aorta and caval vein were 
clamped and end-to-side anastomoses were performed between the recipient 
aorta and caval vein and the donor superior mesenteric artery and portal vein 
respectively. The recipient small bowel was resected, and the graft was placed in-
continuity by end-to-end anastomoses, proximally with the hosfs duodenum and 
distally to the remaining terminal ileum. 
Postoperative monitoring: all rats were weighed 3 times a week during the first 
month, weekly until 3 months posttransplant and every other week during the 
rest of the follow-up period. All animals that died within 4 days were considered 
technical failures. 
Immunosuppression: CsA was administered as described in chapter 2. 
Biochemistry determinations: total serum protein concentration was measured by 
means of the Biuret method and albumin levels by means of the bromcresol-
green method (Boehringer Mannheim GmBH). Triglyceride levels were 
determined colorimetrically, using the triglycerides GPO PAP system 
(Boehringer Mannheim GmBH). The Monotest cholesterol (Boehringer 
Mannheim GmBH) was used to measure serum cholesterol levels. Fecal fat 
excretion and percentage of split fatty acids, were determined using the method 
of van de Kamer et aL (1949). The pH of feces was measured using a standard 
pH electrode. Plasma CsA trough levels were measured using the cyclo-Trac SP 
RIA kit (INCSTAR Corp. Stillwater, Minnesota, USA). 
Statistics: for statistical analysis of the nutritional data analysis of variance 
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(ANOVA) followed by a Student-Newman-Keuls t-test were performed using 
SPSS/PC+. Survival data were analysed using Wilcoxons' rank-sum test. 
EXPERIMENTAL GROUPS 
Experimental groups to study Junctional variables; 
Group 1: normal healthy WAG rats (n:5). 
Group 2: syngeneic total SBT (length approximately 45 em) from WAG to WAG 
rats (n:S). 
Group 3: syngeneic segmental SBT ( :t 10 em of proximal jejunum) from WAG to 
WAG rats (n:3). 
Group 4: fully allogeneic transplantation of the total small bowel (length 
approximately 45 em) from BN to WAG rats (n:7). To prevent rejection, 
recipients were treated with CsA, 15 mg/kg given intramuscularly on days 
0,1,2,4, and 6 after transplantation. 
Group 5: near total small bowel resection in WAG rats. The remnant of the 
terminal ileum (:t 5 mm) was anastomosed to the duodenum (n:3). 
Experimental groups to study CsA absorption and allograft survival; 
Group 6: normal healthy BN rats treated with CsA, 25 mg/kg orally on days 
0,1,2,4, and 6 (n:4). 
Group 7: fully allogeneic transplantation of the total small bowel from WAG to 
BN rats. CsA, 25 mg/kg was administered orally on days 0,1,2,4, and 6 after 
transplantation (n:5). 
Group 8: short bowel controls; BN rats underwent near total small bowel 
resection and subsequent anastomoses of the bowel remnants. The animals were 
given CsA, 25 mg/kg orally on days 0, 1,2,4, and 6 after surgery (n :2). 
Group 9: fully allogeneic transplantation of the total small bowel from WAG to 
BN rats. CsA, 25 mg/kg was given intramuscularly on days 0,1,2,4, and 6 after 
transplantation (n:10). 
Plasma trougb levels of CsA were measured at regular intervals in groups 6, 7, 
and 8. 
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RESULTS 
Nutritional variables 
Between 3 and 7 months after transplantation the following parameters were 
studied: body weight, total serum protein, albumin and triglyceride levels, 
cholesterol values, amount of fecal fat, percentage of split fatty acids in feces, 
and the pH of the feces. 
Total serum protein and albumin levels were equal in all the groups tested 
(Table 1), except in the short bowel control animals (group 5), in which all the 
nutritional parameters were significantly lowered. Serum triglyceride levels, 
however, were significantly reduced as compared with normal, healthy WAG rats 
(group 1) in the syngeneic total smaii bowel transplanted animals (group 2), the 
animals transplanted with 10 em of proximal jejunum (group 3), the group 
transplanted with an aiiogeneic total small bowel treated with CsA (group 4), 
and the short bowel control group. There were no significant differences in 
cholesterol levels between the groups examined. Fecal fat excretion in group 2 
was decreased. There were no differences in the percentage of split fatty acids in 
feces among any of the groups. The pH of the feces in all the groups was ;;, 63. 
Recipient growth 
Fig. 1 shows the weight curves of the smaii bowel resected rats (group 5) and the 
animals transplanted with a syngeneic total small bowel from WAG to WAG 
(group 2) in which no rejection occurs. There is a clear benefit from syngeneic 
SBT in terms of growth as compared to animals without a small bowel. Although 
one short bowel control rat even increased in weight the two others only lost 
weight. Despite their short bowel status, the animals lived on standard laboratory 
rat chow for a long time. Eventually these animals had to be kiiied on days 28, 
61, and 196 after surgery because of their poor condition. 
Up to 1 year after transplantation, there were no· significant differences in 
growth among normal age-matched WAG rats and syngeneic and allogeneic total 
small bowel transplanted animals (Fig. 2). The animals transplanted with a 
jejunal segmental graft were significantly impaired in their growth and, in 
contrast to the other transplanted groups had not reached a normal weight after 1 
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Table 1. Nutritional status after small bowel transplantation. Mean valnes ± 
standard deviation and statistical significances. 
group serum serum serum serum fecal fecal 
protein albumin cholest triglyc fat fatty acid 
(g/l) (mg/ml) (mmolfl) (mmol/l) (g/100g) (% split) 
1. 69.0± 1.3 37.4±0.5 1.6±0.1 1.2±0.3 3.2±0.2 70±2 
2. 65.0±1.5 35.0±2.6 1.9±0.4 o.9± o.z· 2.3±0.4' 73±9 
3. 67,1 ± 1.3 33.4± 1.1 1.5±0.1 0.6±0.2' 2.9±0.4 78±4 
4. n.d. 34.2± 1.8 1.5±0.3 0.9±0.1' 3.0±0.5 71±11 
5. 35.4±8.2' 27.9± 6.8' 0.4±0.2' 0.4±0.1' n.d. n.d. 
Functional parameters were studied between 3 and 7 months after 
transplantation. 
Group 1: normal healthy WAG rats; group 2: syngeneic total small bowel 
transplantation from WAG to WAG rats; group 3: syngeneic segmental small 
bowel transplantation from WAG to WAG rats; group 4: fully allogeneic 
transplantation of the total small bowel from BN to WAG rats; and group 5: 
near total small bowel resected WAG rats. 
•: p<0.05, Student-Newman-Keuls t-Test compared with group 1. 
year. 
CsA absorption after oral administration in SET 
Twenty-four hours after transplantation and after CsA administration high levels 
were measured (Fig. 3). In normal, healthy BN rats the mean level was 765 ± 47 
(mean ± SE) ng/ml, in transplanted animals 882 ± 270 ng/ml, and in short 
bowel controls 14 ± 4 ng/ml. On days 2, 4, and 6 after CsA administration even 
higher levels were found both in the normal animals (group 6) and in the 
transplanted animals (group 7). The small bowel resected animals (group 8) 
failed to absorb considerable amounts of CsA 
The effect of oral CsA administration on graft survival was inferior to 
intramusculair treatment, the former giving a mean graft survival time (MS1) of 
24.2 ± 16 days, the latter a MST of 38.3 ± 27 (p < 0.05, see Table 2). 
123 
Chapter 9 
Table 2. Small bowel allograft survival after oral and intramuscular cyclosporine 
treatment. 
treatment' 
oral 
intramuscular 
survival in days 
8,8,27,36,43 
8,11,13,13,21,55,59,65,66,72 
MST±SD 
24.2±16 
383±27.0" 
1: cyclosporine was given at a dose of 25 mg/kg on days 0,1,2,4, and 6 after 
transplantation. 
2: p < 0.05 versus group 2, Wilcoxon rank-sum test. 
DISCUSSION 
In this study we show that SBT is able to overcome the symptoms of a short 
bowel syndrome. The nutritional status of the animals transplanted with a 
syngeneic total small bowel graft was significantly better than that of animals 
that underwent near-total small bowel resection. Moreover, the transplanted 
animals grew whereas short bowel controls showed a severely impaired 
development, or were unable even to maintain their preoperative body weight. 
This is in accordance with results obtained in dogs by Diliz-Perez et al. (1984), 
and in rats by Oki et al. (1989), and Kimura et al. (1987), the only other studies 
in which a short bowel group was investigated. We could not confirm the earlier 
finding by Somtino et al. (1989) that in BN rats the cecum has to be resected to 
create a lethal short bowel syndrome after extensive small bowel resection. In 
their study, however, 3 em of small bowel was left, whereas in our study only 
abont 1 em remained. This underlines the importance of near-total resection, 
since only a few em of preserved small bowel apparently enables sufficient 
adaptation to sustain the animal's growth. 
There were no significant differences in total serum protein and albumin levels 
among the different groups. In contrast to Raju et al. (1989), who found normal 
total serum protein levels in spite of decreased albumin levels caused by an 
increase in globulin in a dog model of autotransplantation, the normal total 
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Fig.I. Growth curves of animals transplanted with a syngeneic total small bowel 
graft (group 2, n;5), and animals that underwent near-total small bowel resection 
(short bowel control group, n ;3). Because of the great inlerindividual variation 
small bowel resected animals are depicted individually. 
serum protein levels in our study are attributable to serum albumin itself. 
Scbraut et a!. (1987) also found in a rat model that serum albumin levels were 
equal to those in normal rats in segmental and total small bowel grafts 12 
months postoperatively. Normal serum albumin levels were also found in a rat 
total small bowel transplant group but, in contrast to our findings, they were 
significantly lowered in segmental transplants (Old et a!. 1989). As has been 
previously reported by others (Oki et al. 1989, Raju et al. 1989) serum 
cholesterol values were normal in all the transplanted groups. Serum 
triglycerides were significantly lowered in all the experimental groups, but 
neither fecal fat excretion nor the percentage of split fatty acids in feces were 
altered. Others have found normal triglyceride levels both in segmental and in 
total small bowel grafts (Schraut et al. 1987, Raju et al. 1989). 
Both fecal fat excretion and percentage of split fatty acids in feces were 
unimpaired, except in the syngeneic total small bowel transplanted animals, in 
which, for unknown reasons, fecal fat excretion was decreased. Others have 
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Fig.2. Growth curves of normal, healthy WAG rats (group I, n=5}, syngeneic (group 
2, n = 5 ), and allogeneic (group 4, n = 7) total small bowel transplanted animals, and 
animals transplanted with a 10 em syngeneic jejunal segmenal graft (group 3, n=3). 
found an increased fecal fat excretion in rats (Schraut et aL 1987), and dogs 
(Diliz-Perez et aL 1984). In this study only triglyceride levels appeared to be a 
moderately sensitive marker of an impaired bowel function. 
The weight curves of the animals did not correspond well with the above-
mentioned nutritional variables. After an initial weight loss in the first 2 weeks 
after transplantation the syngeneic total small bowel grafted and allogeneic long-
surviving animals began to grow steadily. At 30 weeks after transplantation, there 
were no differences in weight between the controls and the total small bowel 
transplanted animals, which confirms results obtained by Lee & Schraut (1986). 
The animals with a 10 em syngeneic jejunal segment (:!: 20% of total length), 
however, showed a significantly impaired growth. Weight after 30 weeks and 
after 1 year was significantly less than that in unoperated controls or total small 
bowel transplanted groups. This shows that although the nutritional parameters 
did not differ significantly among each other, the weight curves did. 
In this rat model of SBT, therefore, weight of the transplanted groups appears to 
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Fig.3. Cyclosporine plasma trough levels after oral administration; 25 mgjkg was 
given in a volume of 0,1-0,2 ml on days 0,1,2,4, and 6 after transplantation. Group 
6: normal healthy controls (n =4), group 7: allogeneic total small bowel 
transplantation (n =5). Group 8: animals which underwent near total small bowel 
resection (n=2). 
be the most important indicator for graft function. We are aware of the fact that 
weight gain alone might not be the optimal parameter for growth since it does 
not reflect the body composition of the animal. Possibly, total body composition 
analysis using total body electrical conductivity, will prove to be a useful tool 
(Bracco et a!. 1983). The (near) normal nutritional parameters, however, at least 
give an indication that body composition of the animals might be acceptable. 
Another important conclusion that we draw from this study is that the function 
of syngeneic segmental grafts is impaired when compared with syngeneic and 
even allogeneic total small bowel transplants. In clinical SBT, segmental 
transplantation will often be the treatment of choice when living-related 
transplantation or pediatric transplantation is considered. Strategies must 
therefore be developed to increase the functional capacity of segmental grafts. 
The importance of this is further stressed by findings in large animal models 
which show that both after autotransplantation (Raju et al. 1989), and after 
allotransplantation of the entire small bowel (Diliz-Perez eta!. 1984), at best the 
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animals attained their preoperative weight, but never exceeded it. 
It is generally thought that CsA absorption after transplantation will be impaired 
because the disrupted lymphatics of the graft are unable to transport this 
lipophilic drug to the blood (Schraut, 1988). Here we show that CsA absorption 
after total small bowel resection is severely impaired, which stresses the 
importance of this site for its absorption. Consistent with findings by Aeder et a!. 
(1984), and LaRosa et a!. (1989), who found that oral and intraluminal CsA 
absorption within 1 week after transplantation did not differ significantly from 
preoperative or control values, oral CsA absorption directly after transplantation 
in our study gave the same plasma levels as in untreated controls. This indicates 
that there must be an alternative mechanism by which CsA is delivered to the 
blood. By administering CsA intraperitoneally in normal dogs, Cohen et a!. 
(1983) have shown that some absorption may take place via the peritoneum. It is 
possible that after transplantation CsA in the lymph leaks into the peritoneal 
cavity through the disrupted lymphatics, and is subsequently reabsorbed. So even 
before lymph vessel continuity is re-established 4 to 10 weeks posttransplant, as 
is conclusively shown to happen (Kocandrle et al. 1966, Schmid et al. 1990), CsA 
can be administered orally. This reabsorption probably does not account for all 
the CsA absorbed, since lower levels are found after intraperitoneal than after 
oral administration (Cohen et al. 1983). It was shown that CsA absorption is 
highly variable and unpredictable during the early postoperative period, and, 
moreover, rejection can impair the ability of the graft to absorb CsA (Cohen et 
al. 1988). It therefore seems justified to advocate parenteral administration as 
the main route, even when lymphatic connections between donor and recipient 
are established. Whether concomitant oral treatment can be of benefit owing to 
local immunosuppressive effects in the graft needs to be investigated. 
In conclusion, this study shows that SBT is able to overcome the symptoms of a 
short bowel syndrome. Nutritional variables after syngeneic and allogeneic 
transplantation are unimpaired, except for plasma triglyceride levels. Recipient 
growth seems to be the most important parameter for graft function in this 
model and reveals that segmental jejunal grafts are unable to sustain a normal 
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growth of the recipient. Oral CsA can be absorbed by small bowel grafted 
animals as efficiently as by normal controls. Immunosuppression is better after 
intramuscular administration. 
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GENERAL DISCUSSION 
The small bowel allograft has proven to be one of the most difficult organs to 
transplant; it is highly immunogenic, and lymphocytes originating from the 
mesenteric lymph nodes and Peyer's patches have the potential to induce graft-
versus-host disease (GVHD). Nevertheless, since small bowel transplantation 
(SBT) is considered the only causal therapy for patients with the short-bowel 
syndrome, a considerable effort is being made by several groups of investigators 
to make SBT a standard procedure for those with short bowel syndrome who 
would depend on total parenteral nutrition for life. 
The studies described in this thesis were performed to investigate various 
immunological and functional aspects of SBT, with the ultimate goal to obtain a 
long-term surviving, properly functioning small bowel transplant. 
In the fully-allogeneic rat model both rejection and GVHD may occur following 
SBT. In most models however, rejection predominates. In our BN to WAG rat 
donor-recipient combination rejection takes place in approximately 12 days in 
untreated recipients of a small bowel allograft (de Bruin et al. 1990', Chapter 7, 
this thesis). Fifty percent of these animals develop a mild, transient form of 
GVHD that starts some 6 days after grafting and lasts for approximately 3 days. 
In the reverse WAG to BN donor-host combination graft rejection usually takes 
place in 17 days (de Bruin et al. 1990"). Thirty-five percent of these animals 
develop GVHD that begins 9.5 days after transplantation and lasts about 4 days. 
Abrogation of GVHD was obtained by irradiation, or by anti-lymphocyte serum 
treatment of the donor. These modalities effectively prevented GVHD, but at 
the same time graft rejection was accelerated. These findings were reported also 
following bone marrow transplantation, in which effective anti-rejection therapy 
is associated with an increased incidence of GVHD (Storb, 1989). These findings 
have led to the hypothesis that a balance exists between rejection and GVHD, 
and that the prescence of GVHD ameliorates the rejection process (Cohen et al. 
1976, Storb et al. 1989, Saat et a!. 1991, de .Bruin et al. 1992). This is further 
supported by the finding that combined liver/small-bowel transplantation induces 
GVHD and leads to permanent graft acceptance in a rat strain combination in 
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which SBT alone leads to rapid rejection without occurrence of GVHD (Zhong 
et al. 1991). It is uncertain whether this balance can be manipulated in man in 
order to use the immunosuppressive effects of GVHD. We have shown that 
irradiation of the donor with 5 Gray, a dose which fails to prevent the onset of 
GVHD in a parent to F1 model (Lee & Schram, 1985), prevented the 
occurrence of clinical GVHD in a fully-allogeneic model. However, when 
recipients of these grafts were treated with cyclosporine A (CsA) similar survival 
data were obtained as in recipients that had received untreated grafts. This is in 
contrast with survival data after donor irradiation with 10 Gray when CsA failed 
to prolong survival as efficiently as in the previously mentioned groups. It thus 
seems possible to manipulate GVHD in such a way that its immunosuppressive 
properties are maintained, while the clinical symptoms are prevented. At 
present, no such delicate immunosuppression is known in the human situation 
and until this is the case we argue that suppression of GVHD by pretreating the 
donor, or graft, is preferred since GVHD is unlikely to be of benefit to a SBT 
patient, and its immunosuppression is uncontrollable and unpredictable. 
Moreover, by pretreating the graft its immunogenicity is concomitantly reduced, 
thereby prolonging graft survival time (Williams eta!. 1988). We have found that 
GVHD may be more severe in immunosuppressed than in untreated recipients 
(de Bruin et al. 1990", de Bruin et al. 1991, Chapters 5 and 7, this thesis). After 
pretreatment of the recipient with CsA some animals display a severe form of 
GVHD, probably because graft lymphocytes are "privileged" since they are 
transferred to a host in which the lymphocytes are already in contact with CsA 
This is not the only mechanism, because severe GVHD was also seen after 
postoperative administration of CsA or FK-506 only (de Bruin et a!. 1990", de 
Bruin et al. 1991, Murase et a!. 1991). Although these observations are 
interesting from an immunological point of view, they may have little impact on 
clinical transplantation, since it is now firmly established that pretreatment of the 
donor or the graft can effectively prevent the occurrence of GVHD (de Bruin et 
al. 19923 ). 
CsA as immunosuppressant prolonged graft survival in the WAG to BN as well 
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as the BN to WAG model, but in the WAG to BN model it was hard to obtain 
consistent long-term survival usiog moderate to high doses of CsA (de Bruin et 
a!. 1990"). Surprisiogly, low doses of CsA gave better results; with a low-dose 
maintenance therapy of 5 mg/kg CsA until day 100 posttransplant, high 
responder BN recipients of a WAG-graft had a mean survival time of 121 days, 
with 67% of the animals surviviog long-term (Chapter 6, this thesis). This could 
mean that the high dosages used previously were toxic to the bowel graft and 
hence negatively influenced graft survival. Indications for this are the reported 
toxicity of CsA on both large and small bowel (Innes et a!. 1988, Crane et a!. 
1990, Sigalet et a!. 1992) and the clinical findings that patients with a stable graft 
do not reject their graft despite relatively low doses of CsA or FK-506 (Goulet et 
a!. 1992, Todo et a!. 1992). We feel therefore that the use of low-dose CsA 
needs more attention and that CsA may prove to be an effective drug io SBT. 
Specific immnnomodulation as a means of improviog graft survival could also 
benefit small bowel allograft survival. Therefore several investigators have tested 
the effect of donor-specific blood transfusions (DST) on the survival of small 
bowel allografts. Unlike in other organ grafts, DST alone did not improve the 
survival of SBT (Martinelli et a!. 1988, de Bruin et a!. 1990b, Fecteau et a!. 1992, 
Fuknzawa et a!. 1991). A synergistic effect between DST and CsA (Martinelli et 
a!. 1988) and FK-506 (Fuknzawa eta!. 1991) has been reported, although we (de 
Bruin et a!. 1990b) and others (Fecteau et a!. 1992) found no synergism. These 
data are ioconclusive as to whether DST are beneficial to small bowel allograft 
survival and this needs further attention. 
Matching of donor and recipient for MHC-antigens may also be helpful io 
ameliorating the rejection response. This has been conviociogly shown by 
Meijssen et al. (1992). They showed in a dog model that CsA treatment led to a 
significant prolongation of graft survival in fully MHC-matched donor-recipient 
combioations as compared to MHC-unidentical combioations. One clinical SBT 
has been performed io a well-matched donor-recipient combination; 5 episodes 
of acute rejection occurred, but good graft function was obtained long-term, 
usiog CsA as main immunosuppressant (Deitz et a!. 1990). Therefore tissue 
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matching may prove helpful in improving the outcome of SBT. 
Because a small bowel transplant is denervated, has suffered ischemia and 
reperfusion injury, its lymphatics are disrupted, and is under immunologic attack 
of the host, changes in its function may be expected. Indeed, changes have been 
found, among others, in stool fat excretion (increased, Schraut et a!. 1987), 
motility (impaired, Sarr et al. 1989), bacterial colonization (overgrowth, Browne 
et al. 1992), and permeability (increased, Sigalet et al. 1992). Whether or not 
these changes have an impact on the well-being and weight course of the 
recipient on the long-term is still uncertain. Rats transplanted with a total small 
bowel isograft or allograft grow normally, and the only child who has a 
functioning transplant is growing and developing normally (Goulet et al. 1992). 
However, rats grafted witb segmental small bowel transplants may develop 
impaired nutritional parameters (Schraut et al. 1987), or grow suboptimally (Oki 
et al. 1992, de Bruin et al. 1992b). In view of this it seems reasonable to 
transplant as much bowel length as possible. 
No standard protocol for preservation of the small bowel graft has been 
developed, nor is it known what maximal ischemic time is tolerable. In a recent 
series of successful SBT a simple preservation method proved to be appropriate; 
simple core cooling of the graft with University of Wisconsin solution without 
extensive flushing of the capillary bed, followed by immersion in an ice bath. 
Even intraluminal washing was omitted, leaving the succus entericus in the graft, 
with no consequent infection from this practice (Todo et al. 1992). Reported 
ischemic times are up to 16 hours (D' Allesandro et al. 1992). 
Restoration of graft barrier function in order to prevent bacterial translocation, 
and prevention of rejection with either new, more potent drugs or with a 
combination of drugs and specific immunomodulation of donor and recipient are 
needed to improve the successrate of SBT. An early marker of rejection could 
obviate the need for graft biopsies. On the long-term, chronic rejection may 
become the major limiting factor of good graft function. 
It should be noted that in most successful clinical cases not only the small bowel 
but also the liver was grafted. The rejection process seems to be less aggressive 
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in these combined-graft recipients. It is important to elucidate the mechanism by 
which the small bowel is protected from rejection in these cases, since this may 
be an important step forward. 
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Small bowel transplantation (SBT) would be the treatment of choice for patients 
with short-bowel syndrome who depend life-long on total parenteral nutrition. 
Although this latter therapy is life-saving for these patients, it is by no means 
ideal, since it is associated with significant morbidity and mortality from 
complications such as hepatic failure and sepsis. 
The small bowel graft is unique among vascularized organ grafts in that it 
includes large amounts of lymphoid tissue. This has two potentially negative 
consequences; it may increase the immunogenicity of the graft, and alloreactive 
cells in the graft have the potential to induce graft-versus-host-disease (GVHD). 
Unfortunately, these problems still hamper successful clinical SBT as an 
established therapy. In this thesis experiments are described performed with the 
aim to study rejection and GVHD, their possible interaction, and strategies for 
their prevention after SBT. Moreover, some functional aspects of SBT were 
studied. 
In Chapter 3 it was found that irradiation of the donor with 5 or 10 Gray (Gy) 
eliminated clinical GVHD, but significantly shortened the survival time of small 
bowel allografts in untreated recipients. Cyclosporine A (CsA) treatment of the 
recipient combined with 10 Gy donor-irradiation led to significantly reduced 
graft survival time as compared with CsA treatment alone, whereas after 
irradiation with 5 Gy, survival times equalled those without graft irradiation. We 
concluded that irradiation effectively prevents GVHD, and that rejection is 
accelerated when GVHD is absent in this fully-allogeneic model. Therefore it 
was postulated that high dosages of irradiation could either increase the 
vulnerability of the graft, or, by eliminating GVHD, remove its 
immunosuppressive effect. 
In Chapter 4 it was shown that treatment of the donor with anti-lymphocyte 
serum eliminated clinical GVHD, and, as was also found in Chapter 3, this led 
to sigoificantly shortened survival times. Postoperative CsA treatment of the 
recipient overruled this accelerated rejection and led to graft survival times 
comparable to those found with CsA treatment alone. In this combined 
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treatment group no clinical GVHD was observed. CsA used for botb donor 
pretreatment and postoperative therapy had was no survival advantage or effect 
on GVHD compared to postoperative CsA treatment alone. The results obtained 
in Chapters 3 and 4 show tbat tbere is a balance between rejection and GVHD, 
and that abrogation of GVHD leads to accelerated rejection. 
Immunosuppression given to tbe recipient may overrule this and lead to long-
term graft survival without GVHD. 
Io Chapter 5 it was found that it was difficult to achieve long-term graft survival 
using CsA monotherapy in the WAG to BN donor-recipient combination. Long-
surviving animals that had received CsA maintenance therapy until day 100 
posttransplant died from chronic rejection after cessation of CsA therapy. In 
contrast, unresponsiveness could easily be induced in tbe BN to WAG donor-
host combination. Fifteen mg/kg of CsA given on days 0,1,2,4, and 6 after 
transplantation led to permanent graft acceptance in 60% of tbe cases. We 
concluded tbat the effect of CsA on rejection and GVHD following SBT is 
dependent on the rat strain combination used. The WAG to BN combination 
exhibits some of the immunological problems seen in large animal models, 
whereas long-term graft survival can be easily induced in the BN to WAG 
model. 
In the WAG to BN donor-recipient combination, pretreatment of the recipient 
with CsA did not lead to statistically significant prolongation of graft survival, 
and was associated with the occurrence of severe GVHD. It was found, however, 
that witb previously untested low-dose CsA maintenance therapy it was possible 
to obtain long-term graft survival. lt was concluded tbat postoperative low-dose 
CsA maintenance therapy with or without donor-irradiation is of benefit to the 
long-term survival of small bowel allografts (Chapter 6). 
Io tbe BN to WAG model, donor-specific blood transfusions given to the 
recipient are very effective in prolonging the survival of heart and kidney 
allografts. In Chapter 7 it was found tbat pretreatment of the recipient with 3 
donor-specific blood transfusions on days -21, -14, and -7 before transplantation 
had no effect on graft survival after transplantation of a total small bowel or a 
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10 centimeter long segment of jejunum or ileum. Combined treatment of the 
recipient with donor-specific blood transfusions and CsA did not improve graft 
survival compared with CsA alone. Unexpectedly, after preconditioning with 
donor-specific blood transfusions, fewer rats showed signs of GVHD. It was 
concluded that donor-specific blood transfusions do not have an effect on small 
bowel allograft survival, but ameliorate GVHD. 
In the WAG to BN donor-host combination, the immunosuppressive agent FK-
506 appeared to be less effective in controlling rejection and GVHD than CsA 
After administration of 2 mg/kg FK-506 on days 0,1,2,4, and 6 after grafting, 
mean survival was prolonged to 285 days, and 88% of these animals developed 
fuhninant GVHD. Additional irradiation of the donor with 5 Gy prevented 
GVHD, but did not lead to better survival times (Chapter 8). 
In Chapter 9 we showed that SBT is able to overcome the symptoms of short 
bowel syndrome. Growth of animals transplanted with a syngeneic or allogeneic 
total small bowel graft equalled that of healthy control animals. Since 
transplantation of a segment of bowel may offer some advantages, animals 
transplanted with a 10 centimeter long jejunal graft were studied. These animals 
showed significantly impaired growth. CsA absorption after oral administration 
in the early postoperative phase was not significantly different from unoperated 
controls, but graft survival after intramuscular CsA administration was 
significantly better than after oral administration. 
Chapter 10 generally discusses the significance of the results presented in 
Chapters 3 to 9, and gives some leads to further investigations. 
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Transplantatie van de dunne darm is theoretisch de beste bebandeling voor 
patienten met het "short bowel" syndroom. Dit ziektebeeld, dat ontstaat na 
uitgebreide darmresectie, wordt gekenmerkt door diarree, steatorrhoe, 
malnutritie en gewichtsverlies. Sinds 1968 worden deze patienten behandeld met 
totale parenterale voeding. Bij een dee! van de patienten adapteert de restdarm, 
waardoor de patient uiteindelijk geheel of gedeeltelijk enteraal gevoed kan 
worden. Bij een subgroep van deze patienten treed! geen adaptatie op, waardoor 
zij levenslang afhankelijk zijn van totale parenterale voeding. Deze therapie is 
echter verre van ideaal vanwege de complicaties die erroee geassocieerd zijn, 
zoals leverfalen en sepsis. Voor deze patienten zou dunne darmtransplantatie 
uitkomst bieden. 
Echter, de dunoe darro bevat vee! lymfoid weefsel in de Peyerse plaques, de 
mesenteriale lymfklieren, en de darmwand. Hierdoor is de darm een zeer 
immunogeen orgaan, en bovendien zijn alloreactieve cellen in het transplantaat 
in staat om in de ontvanger van dat transplantaat een zogenaamde graft-versus-
host reaktie (GVHR) te veroorzaken. Deze problemen staan klinische toepassing 
van dunoe darmtransplantatie als standaardtherapie voor mensen met het "short 
bowel" syndroom nog steeds in de weg. 
In dit proefschrift worden experimenten beschreven die uitgevoerd zijn in de rat 
teneinde afstoting en G VHR, de mogelijke interactie tussen deze processen en 
de beinvloeding ervan te bestuderen. Daarnaast zijn nog enkele functionele 
aspecten van dunoe darrntransplantatie bestudeerd, met het uiteindelijke doe! 
om dunoe darmtransplantatie in de mens mogelijk te maken. 
In hoofdstuk 1 word! een overzicht gegeven van de huidige stand van zaken in 
het dunne darrotransplantatie onderzoek. 
In hoofdstuk 3 word! beschreven dat na bestraling van de orgaandonor met 5 of 
10 Gray (Gy) de GVHR onderdrukt werd, maar dat tegelijkertijd een 
significante verkorting van de overlevingstijd van het transplantaat werd 
gevonden. Behandeling van de transplantaat ontvanger met het 
immunosuppressivum cyclosporine A (CsA), gecombineerd met bestraling van de 
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donor met 10 Gy, leidde tot een verkorte overlevingstijd ten opzichte van CsA 
behandeling alleen. CsA hebandeling gecombineerd met 5 Gy bestraling van de 
donor leidde tot eenzelfde overlevingstijd als behandeling met CsA alleen. In 
deze groep werd echter geen klinische GVHR meer gezien. Er werd 
gekonkludeerd dat bestraling van de donor effectief de GVHR kan 
onderdrukken, en dat dit leidt tot een versnelde afstoting van bet 
darmtransplantaat. De mogelijke oorzaak hiervan is dat hoge doses bestraling 
het transplantaat kunnen beschadigen, of dat het immunosuppressieve effect dat 
veroorzaakt wordt door GVHR, bij afwezigheid van GVHR een s,nellere 
afstoting mogelijk maakt. 
In hoofdstuk 4 werd gevonden dat behandeling van de donor met anti-
lymfocyten serum (ALS) de GVHR onderdrukte en dat, zoals ook in hoofdstuk 3 
werd gevonden, tegelijkertijd de overlevingstijd korter werd. Behandeling van de 
ontvanger met CsA, in combinatie met voorbehandeling van de donor met ALS, 
leidde tot een overlevingstijd vergelijkbaar met CsA behandeling alleen, en ook 
bier werd geen GVHR meer gezien. Wanneer CsA zowel aan de donor als aan 
de ontvanger werd toegediend, werd geen betere transplantaatoverleving of 
verandering in optreden van GVHR gezien in vergelijking tot CsA behandeling 
van alleen de ontvanger. De resultaten die beschreven zijn in de hoofdstukken 3 
en 4 geven aan dat er een balans bestaat tussen afstoting en GVHR; wanneer de 
GVHR wordt onderdrukt treed! er een versnelde afstoting op, die echter teniet 
kan worden gedaan door de ontvanger te behandelen met CsA Dit leidt dan tot 
een langdurige overleving in afwezigheid van klinische GVHR. 
In de WAG naar EN-rat donor-ontvanger combinatie bleek bet moeilijk om 
langdurig overlevende dieren te krijgen met CsA behandeling aileen. Dieren die 
langdurig hun transplantaat behielden onder CsA onderhoudstherapie, stierven 
alsnog aan de gevolgen van chronische afstoting wanneer deze 
onderhoudstherapie 100 dagen na transplantatie gestaakt werd. In de 
omgekeerde BN naar WAG donor-ontvanger combinatie kon al met een 
dosering van 15 mg/kg CsA gegeven op dagen 0,1,2,4, en 6 na transplantatie 
langdurige ( > 200 dagen) overleving verkregen worden in 60% van de gevallen. 
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Er werd gekonkludeerd dat het effect van CsA op afstoting en GVHR 
afhankelijk is van de donor-ontvanger combinatie die wordt gebruikt. In de 
WAG naar BN combinatie worden gedeeltelijk dezelfde problemen gezien als in 
bet grote proefdiermodel, namelijk een moeilijk te beheersen afstotingsreaktie, 
terwijl in bet omgekeerde model gemakkelijk langdurige transplantaatoverleving 
bereikt kan worden (hoofdstuk 5). In bet WAG naar BN model leidde ook 
voorbehandeling van de ontvanger met CsA niet tot significant langere 
overlevingstijden vergeleken met postoperatieve CsA behandeling aileen. We! 
trad bij voorbehandeling een ernstige vorm van GVHR op. In deze studie werd 
ook gevonden dat met een !age onderhoudsdosering van 5 mgjkg CsA 
langdurige transplantaatoverleving verkregen kon worden, en kon worden 
gekonkludeerd dat een !age dosis CsA als onderhoudsdosering aileen, of 
gecombineerd met bestraling van de donor, een langdurige 
transplantaatoverleving kan garanderen (hoofdstuk 6). 
Donor-specifieke bloedtransfusies gegeven aan de ontvanger v66r transplantatie, 
leiden in het BN naar WAG model tot een langdurige verlenging van de 
overleving van hart-, en niertransplantaten. In hoofdstuk 7 wordt beschreven dat 
toediening van donor-specifieke bloedtransfusies aan de ontvanger niet leidt tot 
een langere darmtransplantaatoverleving. Het "bloedtransfusie effect" werd noch 
gevonden na transplantatie van de gehele dunne darm, noch na transplantatie 
van 10 centimeter jejunum of ileum. Gecombineerd met CsA therapie werd geen 
betere transplantaatoverleving gevonden dan na CsA behandeling alleen. Wel 
trad na toediening van donor-specifieke bloedtransfusies bij minder dieren 
GVHRop. 
In de WAG naar BN combinatie bleek bet immunosuppressivum FK-506 minder 
werkzaam te zijn tegen afstoting en GVHR dan CsA Twee mg/kg FK-506 
gegeven op dagen 0,1,2,4, en 6 na transplantatie gaf een gemiddelde 
overlevingstijd van 28,5 dagen. Achtentachtig procent van deze dieren 
ontwikkelden een ernstige vorm van GVHR. Wanneer de donor bestraald werd 
met 5 Gy werd geen GVHR meer gezien, maar de gemiddelde overleving werd 
niet beter (hoofdstuk 8). 
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In hoofdstuk 9 wordt aangetoond dat een dunne darm transplantaat de 
symptomen van het short bowel syndroom kan genezen. De groei van dieren die 
een syngeen of allogeen darmtransplantaat hadden ontvangen was gelijk aan die 
van gezonde, niet getransplanteerde dieren. Omdat transplantatie van een dee! 
van de dunne darm in sommige gevallen voordelen heeft, werden ook dieren 
bestudeerd die getransplanteerd waren met een transplantaat van 10 em 
jejunum. Deze dieren groeiden slechter dan dieren die een gehele darm hadden 
ontvangen. 
In de vroege postoperatieve fase verschilde de absorptie van oraal toegediende 
CsA niet van die in gezonde controle dieren. De immunosuppressie was na 
intramusculaire toediening echter beter dan na orale toediening. 
In hoofdstuk 10 worden de resultaten besproken die gevonden werden in de 
hoofdstukken 3 t/m 9, en worden enkele suggesties voor verder onderzoek 
gedaan. 
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LIST OF ABBREVIATIONS 
AlS 
CsA 
DST 
GVHD 
GVHR 
Gy 
HESS 
HSBT 
IEL 
Jg 
im 
ip 
iv 
kg 
mg 
MHC 
ml 
MMC 
MST 
NAH 
OSBT 
pp 
RAPA 
SB 
SBS 
SBT 
SD 
SE 
TNF-a 
TPN 
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anti-lymphocyte serum 
cyclosporine A 
donor-specific blood transfusion 
graft-versus-host disease 
graft-versus-host reaktie 
Gray 
Hanks balanced salt solution 
heterotopic small bowel transplantation 
intra-epithelial lymphocyte 
immunoglobulin 
intramuscularly 
intraperitonea!ly 
intravenously 
kilogram 
milligram 
major histocompatibility complex 
milliliter 
migrating motor complex 
mean survival time 
N-acetyl hexosaminidase 
orthotopic small bowel transplantation 
Peyer's patch 
Rapamycin 
small bowel 
short bowel syndrome 
small bowel transplantation 
standard deviation 
standard error of the mean 
tumor necrosis factor alpha 
total parenteral nutrition 
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